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Abstract
This 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment
Recommendations for advanced life support includes updates on multiple advanced life support topics addressed with 3 different types of reviews.
Topics were prioritized on the basis of both recent interest within the resuscitation community and the amount of new evidence available since any
previous review. Systematic reviews addressed higher-priority topics, and included double-sequential defibrillation, intravenous versus intraosseous
route for drug administration during cardiac arrest, point-of-care echocardiography for intra-arrest prognostication, cardiac arrest caused by pulmonary
embolism, postresuscitation oxygenation and ventilation, prophylactic antibiotics after resuscitation, postresuscitation seizure prophylaxis and
treatment, and neuroprognostication. Newor updated treatment recommendations on these topics are presented. Scoping reviewswere conducted for
anticipatory charging and monitoring of physiological parameters during cardiopulmonary resuscitation. Topics for which systematic reviews and new
Consensuses on Science With Treatment Recommendations were completed since 2015 are also summarized here. All remaining topics reviewed
were addressed with evidence updates to identify any new evidence and to help determine which topics should be the highest priority for systematic
reviews in the next 1 to 2 years.
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Overview
The International Consensus on Cardiopulmonary Resuscitation
(CPR) and Emergency Cardiovascular Care (ECC) Science With
Treatment Recommendations (CoSTR) is the fourth in a series of
annual International Liaison Committee on Resuscitation (ILCOR)
publications. This 2020 CoSTR for advanced life support (ALS)
includes new topics addressed by systematic reviews performed
within the past 12 months and prioritized by the ALS Task Force. In
addition, it includes updates of the ALS treatment recommendations
that were published from 2010 through 2019,1  8 as needed, andwere
based on additional evidence evaluations. As a result, this
2020 CoSTR for ALS is the most comprehensive update since
2010. The 3 major types of evidence evaluation supporting this
2020 publication are the systematic review (SysRev), the scoping
review (ScopRev), and the evidence update (EvUp).
The SysRev is a rigorous process following strict methodology to
answer a specific question, and each of these ultimately resulted in
generation of the task force CoSTR included in this publication. The
SysRevs were performed by a Knowledge Synthesis Unit, an Expert
Systematic Reviewer, or by theALS Task Force, andmany resulted in
separate published SysRevs.
To begin the SysRev, the question to be answered was phrased in
terms of the population, intervention, comparator, outcome, study
design, time frame (PICOST) format. The methodology used to
identify the evidence was based on the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA).9 The approach
used to evaluate the evidence was based on the one proposed by the
Grading of Recommendations, Assessment, Development and
Evaluation (GRADE) working group.10 Using this approach, the task
force rated as high, moderate, low, or very low the certainty/
confidence in the estimates of effect of an intervention or assessment
across a body of evidence for each of the predefined outcomes.
Randomized controlled trials (RCTs) generally began the analysis as
high-certainty evidence, and observational studies generally began
theanalysis as low-certainty evidence; examinationof theevidenceby
using the GRADE approach could result in downgrading or upgrading
of the certainty of evidence. For additional information, refer to Part 2:
Evidence Evaluation Process and Guidelines Development in this
supplement.11[1874_TD$DIFF],11a
When we have quoted unchanged treatment recommendations
from the 2010 CoSTR, the language used differs from that in the
GRADE approach because GRADE was not used before 2015.12,13
Draft 2020 CoSTRs for ALS were posted on the ILCOR website14
for public comment between January 3 and January 4, 2020, with
comments accepted through January 18, 2020. These new draft
2020 CoSTR statements for ALS were viewed a total of 4205 times
with 11 comments received.
This summary statement contains the final wording of the CoSTR
statements as approved by the ILCOR task forces and by the ILCOR
member councils after review and consideration of comments posted
online in response to the draft 2020 CoSTRs. Within this publication,
each topic includes the PICOST as well as the CoSTR, an expanded
Justification andEvidence-to-Decision FrameworkHighlights section,
and a list of knowledge gaps requiring future research studies. An
evidence-to-decision table is included for each CoSTR in Appendix A
in the Supplemental Materials of this publication.
Thesecondmajor typeof evidenceevaluationperformed to support
this 2020 CoSTR for ALS is a ScopRev, which identifies the extent,
range, and nature of evidence on a topic or a question. The ScopRevs
were performed by topic experts in consultation with the ALS Task
Force. The task force analysed the identified evidence and determined
its value and implications for resuscitation practice or research. The
rationale for the ScopRev, the summary of evidence, and task force
insights are all highlighted in the body of this publication. The most
recent treatment recommendation is included. The task force notes
whether theScopRev identified substantive evidence thatmay result in
a change in ILCOR treatment recommendations. If sufficient evidence
was identified, the task force suggested consideration of a future
systematic review to supply sufficient detail to support the development
of an updated CoSTR. All ScopRevs are included in their entirety in
Appendix B in the Supplemental Materials of this publication.
The third type of evidence evaluation supporting this 2020 CoSTR
for ALS is an EvUp. EvUps are generally performed for topics
previously reviewed by ILCOR to identify new studies published after
the most recent ILCOR evidence evaluation, typically through use of
search terms and methodologies from previous reviews. These
EvUps were performed by task forcemembers, collaborating experts,
or by members of council writing groups. The EvUps are cited in the
body of this publication with reiteration of the original PICOST (if
available) and a note as to whether the evidence suggested the need
to consider a SysRev; the existing ILCOR treatment recommendation
is quoted. In this publication, no change in ILCOR treatment
recommendations resulted from an EvUp; if substantial new evidence
was identified, the task force recommended consideration of a
SysRev. All EvUps are included in Appendix C in the Supplemental
Materials of this publication.
TheALSTaskForce considered theavailability of newevidenceas
well as the evidence needed to create, confirm, or revise treatment
recommendations. The chapter topics are organized in sections
according to the approximate order of the steps of resuscitation,
postresuscitation care, and prognostication. For each reviewed topic,
the method of review (SysRev, ScopRev, EvUp) is clearly labelled,
with links to the relevant review documents in the Appendix.
Topics Reviewed in This 2020 ALS CoSTR
Note: As indicated above, the ALS CoSTR evidence reviews were all
completed by January 18, 2020. As a result, this document does not
address the topic of potential influence of coronavirus disease 2019
(COVID-19) on resuscitation practice. In the spring of 2020, an ILCOR
writing group was assembled to identify and evaluate the published
evidence regarding risks of aerosol generation and infection
transmission during attempted resuscitation of adults, children, and
infants. This group developed a consensus on science with treatment
recommendations and task force insights. This statement is published
asaseparatedocument.15 Asnewevidenceemerges, the ILCOR task
forces will review and update this statement, so the reader is referred
to the ILCOR website14 for the most up-to-date recommendations.
Defibrillation Strategies for Ventricular Fibrillation or Pulse-
less Ventricular Tachycardia
 Anticipatory defibrillator charging (ALS 2001: ScopRev)
 Double sequential defibrillation (ALS 2003: SysRev)
 Automated external defibrillator versus manual defibrillator (ALS
495: EvUp)
 Waveform analysis for predicting successful defibrillation (ALS
601: EvUp)
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Airway, Oxygenation, and Ventilation During CPR
 Airway management during cardiac arrest (ALS 576, 783, 432,
496, 711, 714: 2019 SysRev, CoSTR update)
 Confirmation of correct tracheal tube placement (ALS 469: EvUp)
 Oxygen dose during CPR (ALS 889: EvUp)
 Automatic ventilators versus manual ventilation during CPR (ALS
490: EvUp)
Circulatory Support During CPR
 ECPR versus manual or mechanical CPR (ALS 723: 2018 Sys-
Rev, 2019 CoSTR)
Physiological Monitoring During CPR
 Monitoring physiological parameters during CPR (ALS 656:
Adopted From Pediatric Task Force ScopRev)
Drugs During CPR, Including Timing of Administration
 Vasopressors during cardiac arrest (ALS 788, 659, 789, 784, 778:
2019 SysRev, CoSTR)
 Antiarrhythmic drugs for cardiac arrest (ALS 428, 493: 2018
SysRev, CoSTR)
 Intravenousversus intraosseousdrugdelivery (ALS2046:SysRev)
 Steroids during cardiac arrest (ALS 433: EvUp)
 Buffering agents for cardiac arrest (ALS 483: EvUp)
 Drugs for torsades de pointes (ALS 457: EvUp)
Intra-arrest Prognostication
 Point-of-care echocardiography for prognostication during CPR
(ALS 658: SysRev)
 ETCO2 to predict outcome of cardiac arrest (ALS 459: EvUp)
Cardiac Arrest in Special Circumstances
 Cardiac arrest associated with pulmonary embolism (ALS 435,
581: SysRev)
 Cardiac arrest in pregnancy (ALS 436: EvUp)
 Opioid toxicity (ALS 441: EvUp)
Postresuscitation Care
 Oxygen dose after return of spontaneous circulation (ROSC) in
adults (ALS 448: SysRev)
 Ventilation strategy after ROSC in adults (ALS 571: SysRev)
 Postresuscitation haemodynamic support (ALS 570: EvUp)
 Postresuscitation steroids (ALS 446: EvUp)
 Prophylactic antibiotics after cardiac arrest (ALS 2000: SysRev)
 Post-cardiac arrest seizure prophylaxis and treatment (ALS 431,
868: SysRev)
 Targeted temperature management (ALS 455, 790, 791, 802,
879: EvUp)
Prognostication in Comatose Patients After Resuscitation
From Cardiac Arrest
 Clinical examination for prognostication (ALS 450, 713, 487:
SysRev)
 Neurophysiological tests for prognostication (ALS 450, 713, 460:
SysRev)
 Blood biomarkers for prognostication (ALS 450, 713, 484:
SysRev)
 Imaging for prognostication (ALS 450, 713, 458: SysRev)
Defibrillation Strategies for Ventricular
Fibrillation or Pulseless Ventricular
Tachycardia
The task force restricted its review to 2 new topics that were based on
trends in current clinical practice. These deal primarily with manual
defibrillation in adults. The CoSTRs for the use of automated external
defibrillators for adults canbe found inAdultBasic LifeSupport, and for
infants and children in Pediatric Life Support.
Anticipatory Defibrillator Charging (ALS 2001: ScopRev)
Rationale for Review
This topic was chosen because the timing of the rhythm check in
relation to manual defibrillator charging varies by country and region.
The standard method described in the 2010 American Heart
Association Guidelines for CPR and ECC16 and the 2015 European
Resuscitation Guidelines17 consists of briefly pausing compressions
to analyse the rhythm then resuming compressionswhile charging the
defibrillator, then pausing compressions briefly to deliver the shock.
With the anticipatory method, the defibrillator is charged near the end
of a compression cycle but before the rhythm is checked; then,
compressions are paused briefly both to analyse the rhythm and
deliver a shock. The ScopRev methodology was chosen given the
limited published evidence.18
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults with cardiac arrest in any setting (in-hospital or
out-of-hospital)
 Intervention: Charging the defibrillator before rhythm analysis
during manual defibrillation
 Comparator: Charging the defibrillator after rhythm analysis
during manual defibrillation
 Outcome: Survival with favourable neurological/functional out-
come at discharge, 30 days, 60 days, 180 days, and/or 1 year;
survival only at discharge, 30 days, 60 days, 180 days, and/or
1 year; ROSC were defined as critical or important outcomes.
Other outcomes were termination of arrhythmia, defibrillation
success, preshock pause, postshock pause, perishock pause,
hands-off time, hands-on time, compression fraction, inappropri-
ate shocks, shocks during chest compression (shock to rescuer),
or any other defibrillation measure.
 Study design: Humanandmanikin studieswere included. RCTs and
nonrandomized studies (non-RCTs, interrupted time series, con-
trolled before-and-after studies, cohort studies) were eligible for
inclusion. Unpublished studies (eg, conference abstracts, trial
protocols) were excluded. In addition, gray literature (evidence not
published in traditional journals) was included in this ScopRev.19,20
 Time frame: All years and languages were included. Studies
without a title in English were excluded. MEDLINE, Embase, and
Cochrane databases were updated to October 7, 2019.
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Summary of Evidence
We identified no clinical studies addressing the critical or important
outcomes specified in the PICOST question. Three manikin and 1
multicentre retrospective human study were identified. In the only
human study,21 both methods resulted in relatively short pre- and
postshock pauses, whereas anticipatory charging was associated
with a shorter total hands-off time in the 30 seconds preceding
shock delivery. The results of the 3 manikin studies showed
reduced overall pause duration during the compression cycle, but
increased pre, post, and perishock pause duration with anticipatory
charging.22  24
Task Force Insights
TheScopRev is included in [1875_TD$DIFF]Supplement Appendix B-1. The task force
noted that although anticipatory charging can reduce overall chest
compression pause duration during the compression cycle, it can
increase pre, post, and perishock pause duration. The clinical
relevance of these findings is undetermined. Further high-quality
evidence is required to evaluate the relative importanceof the different
types of pause duration for critical and important patient outcomes,
and the role of new defibrillator technologies and methods. There are
insufficient data for a SysRev to be of use at this time.
Treatment Recommendation
There was no treatment recommendation on timing of defibrillator
charging previously, and in the absence of sufficient evidence, none
was added.
Double Sequential Defibrillation (ALS 2003: SysRev)
Rationale for Review
This is a new topic in response to the increasing use of double (dual)
sequential defibrillation (DSD). At least 20% of patients with
ventricular fibrillation (VF)/pulseless ventricular tachycardia (pVT)
will remain in a shockable rhythm after 3 shocks.25  28 Survival
decreases as the number of defibrillation attempts required increases.
DSD, or the use of 2 defibrillators to deliver 2 overlapping shocks or
2 rapid sequential shocks, one with standard pad placement and the
other with either anteroposterior or additional anterolateral pad
placement, has been suggested as a possiblemeans of increasingVF
termination rates.
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults with cardiac arrest in any setting (in-hospital or
out-of-hospital) with a shockable rhythm
 Intervention: DSD
 Comparator: Standard defibrillation
 Outcome:Favourable neurological outcomeat hospital discharge,
survival to hospital discharge or admission, ROSC, or termination
of VF
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies with 5 patients or more) are eligible for inclusion.
 Time frame: There was no date restriction, and the literature
search was updated to September 27, 2019.
 International Prospective Register of Systematic Reviews
(PROSPERO) Registration: CRD42020152575
Consensus on Science
For the critical outcomes of survival with favourable neurological
outcome29  31 and survival to hospital discharge29  34 and the
important outcomes of survival to hospital admission,29,30,32,33
ROSC,29  35 and termination of VF,31,34,35 we identified only
observational studies. The overall certainty of evidence was rated
as very low for all outcomes, primarily because of a very serious risk of
bias. The individual studies were all at a critical or serious risk of bias
because of confounding (due to inadequate adjustment for cardiac
arrest characteristics and other factors). Because of this and a high
degree of heterogeneity, no meta-analyses could be performed, and
individual studies were difficult to interpret.36
Treatment Recommendation
We suggest against routine use of a DSD strategy in comparison with
a standard defibrillation strategy for cardiac arrest with a shockable
rhythm (weak recommendation, very low-certainty evidence).
Justification and Evidence-to-Decision Framework Highlights
Theevidence-to-decision table is included in [1875_TD$DIFF]Supplement AppendixA-1.
There is nostrongevidence to favourone intervention comparedwith the
other. Theevidenceavailable (very lowcertainty) suggests lower ratesof
survival and neurological outcome for patients treatedwith DSD, but any
odds ratios (ORs) or other results reported are difficult to interpret given
theveryhighriskofbias.36There isnoconsensusstandardizedapproach
to double defibrillation, in that a double-dose strategy could be
2 overlapping shocks or 2 sequential shocks. The ALS Task Force
discussedwhetheranypotentialbenefitmightarise fromincreasedshock
energy, the fact that 2 shocks were delivered sequentially, different pad
placement and vector for the second shock, or some other reason. The
task force is aware of recently published data from a small pilot RCT
comparing standard defibrillation to DSD (adding a second set of
defibrillator pads in the anteroposterior position) or to vector change
defibrillation (replacing anterolateral pads with anteroposterior pads).37
The study found differences in VF termination (DSD76%, vector change
82%, and standard placement 66%) and ROSC (DSD 40%, vector
change 39%, and standard defibrillation 25%). This pilot RCT was not
designed to formally test differencesbetween thegroups,andnosurvival
data were reported. These results have informed a larger, ongoing RCT
(NCT04080986) that will provide further data about DSD.
Implementation of DSD requires training of staff and availability of
defibrillators. It is important to monitor the intervention to determine
effectiveness, and to track adverse events such asharm to the patient,
defibrillator damage, and the increase in resource utilization.
Knowledge Gap
High-quality studies comparing DSD with standard defibrillation in
terms of survival and neurological outcome at hospital discharge
Automated External Defibrillator Versus Manual Defibrillator
(ALS 495: EvUp)
Population, Intervention, Comparator, and Outcome
 Population: Adults who are in cardiac arrest in any setting (in-
hospital or out-of-hospital)
 Intervention: Use of an automated external defibrillator or a
multifunctional defibrillator in automatic mode
 Comparator: Standard resuscitation (using a manual defibrillator)
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 Outcome:Favourable neurological outcomeat hospital discharge,
survival to hospital discharge or admission, ROSC, or termination
of VF
 This topic was last reviewed in 2010.43,44 The evidence update is
included in [1876_TD$DIFF]Supplement Appendix C-1 and the search conducted
was limited to January 2008 to December 2019. We identified
5 observational studies (only 2 of which included a comparison
group) and no randomized trials.38  42 After consideration, a
SysRev was not suggested.
Treatment Recommendation
This treatment recommendation (below) is unchanged from2010.43,44
No significant survival differences have been demonstrated
between defibrillation in semiautomatic and manual modes during
out-of-hospital or in-hospital resuscitation; however, the semiauto-
matic mode is preferred because it is easier to use and may deliver
fewer inappropriate shocks.
Trained personnel may deliver defibrillation in manual mode. Use
of the manual mode enables chest compressions to be continued
during charging, therebyminimizing the preshock pause.When using
the defibrillator in manual mode, frequent team training and ECG
recognition skills are essential.
The defibrillation mode that results in the best outcome will be
influenced by the system of care and by provider skills, training, and
ECG recognition.
Waveform Analysis for Predicting Successful Defibrillation
(ALS 601: EvUp)
Population, Intervention, Comparator, and Outcome

Population: Adults with cardiac arrest in any setting (in-hospital or
out-of-hospital)
 Intervention: Use of techniques for prediction of the likelihood of
success of defibrillation (analysis of VF, etc)
 Comparator: Standard resuscitation (without such prediction)
 Outcome: Survival with favourable neurological/functional out-
come at discharge, 30 days, 60 days, 180 days, and/or 1 year;
survival only at discharge, 30 days, 60 days, 180 days, and/or
1 year; ROSC; termination of VF
 This topic was last reviewed in 2010.43,44 Two EvUps were
completed for 2020 and are included in [1876_TD$DIFF]Supplement Appendix C-
2a and C-2b. The evidence updates restricted the search to
January 2008 to January 2020 and identified one large RCT
conducted in 201345 and 20 observational studies.46  65 In
addition, there is an ongoing multicentre RCT of real-time
amplitude spectrum area to guide defibrillation (NCT03237910).
Although the VF waveform analyses and outcomes studied were
highly heterogeneous, given the amount of data available, an
updated SysRev was suggested.
Treatment Recommendation
This treatment recommendation (below) is unchanged from2010.43,44
There is insufficient evidence to support routine use of VF
waveformanalysis to guide defibrillationmanagement in adult cardiac
arrest in- or out-of-hospital.
Airway, Oxygenation, and Ventilation During
CPR
Airway Management During Cardiac Arrest (ALS 576, 783,
432, 496, 711, 714: 2019 SysRev, CoSTR Update)
Airway management during cardiac arrest was addressed by a 2019
SysRev66 and a 2019 CoSTR summary.2,3 Consensus on science,
justification and evidence-to-decision highlights, and knowledge gaps
can be found in the 2019 CoSTR summary.2,3
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults with cardiac arrest from any cause and in any
setting (in-hospital or out-of-hospital)
 Intervention:A specific advancedairwaymanagementmethod (eg,
tracheal intubation or a supraglottic airway) during cardiac arrest
 Comparator: A different advanced airwaymanagementmethod or
no advanced airway management method (eg, bag-mask
ventilation) during cardiac arrest
 Outcome:ROSC, survival, or survivalwith favourable neurological
outcome at discharge/28 days or longer
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) that compared at least 2 airway strategieswereeligible for
inclusion. Studies with 10 or fewer patients in either group were
excluded.
 Time frame: All years and languages were included; unpublished
studies (eg, conference abstracts, trial protocols) were excluded.
The literature search was updated to October 30, 2018.
Treatment Recommendations
We suggest using bag-mask ventilation or an advanced airway
strategy during CPR for adults with cardiac arrest in any setting (weak
recommendation, low to moderate certainty of evidence).
If an advanced airway is used, we suggest a supraglottic airway for
adults with out-of-hospital cardiac arrest (OHCA) in settingswith a low
tracheal intubation success rate (weak recommendation, low-
certainty evidence).
If an advanced airway is used, we suggest a supraglottic airway or
tracheal intubation for adults with OHCA in settings with a high
tracheal intubation success rate (weak recommendation, very low-
certainty evidence).
If an advanced airway is used, we suggest a supraglottic airway or
tracheal intubation for adults with in-hospital cardiac arrest (IHCA)
(weak recommendation, very low-certainty evidence).2,3
Confirmation of Correct Tracheal Tube Placement (ALS 469:
EvUp)
Population, Intervention, Comparator, and Outcome
 Population: Adults with cardiac arrest in any setting (in-hospital or
out-of-hospital) requiring tracheal intubation
 Intervention: Use of devices (eg, waveform capnography, CO2
detection device, esophageal detector device, or tracheal
ultrasound)
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 Comparator: Not using these devices
 Outcome: Tracheal intubation success
 This topic was last reviewed in 2015.1,7 This EvUp is included in [1876_TD$DIFF]
Supplement Appendix C-3. An updated SysRev was not
considered necessary.
Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.1,7
We recommend using waveform capnography to confirm and
continuously monitor the position of a tracheal tube during CPR in
addition to clinical assessment (strong recommendation, low-quality
evidence).
We recommend that if waveform capnography is not available, a
nonwaveform CO2 detector, esophageal detector device, or ultra-
sound in addition to clinical assessment is an alternative (strong
recommendation, low-quality evidence).1,7
Oxygen Dose During CPR (ALS 889: EvUp)
Population, Intervention, Comparator, and Outcome
 Population: Adults with cardiac arrest in any setting (in-hospital or
out-of-hospital)
 Intervention: Administering a maximal oxygen concentration (eg,
100% by face mask or closed circuit)
 Comparator: No supplemental oxygen (room air) or an alternative
supplemental oxygen concentration (eg, 40% to 50%)
 Outcome: Survival with favourable neurological/functional out-
come at discharge, 30 days, 60 days, 180 days, and/or 1 year;
survival only at discharge, 30 days, 60 days, 180 days, and/or 1
year; ROSC
 This topic was last reviewed in 2015.1,7 This EvUp is included
in [1876_TD$DIFF]Supplement Appendix C-4 and the search was conducted
from October 30, 2013, to December 2, 2019. The search
identified 2 observational studies relevant to this topic
published since 2015.67,68 There are no adult studies of
oxygen titration during CPR. An updated SysRev was not
considered necessary.
Treatment Recommendation
This treatment recommendation (below) is unchanged from 2015.1,7
We suggest using the highest possible inspired oxygen concen-
tration during CPR (weak recommendation, very low-certainty
evidence).
Automatic Ventilators Versus Manual Ventilation During CPR
(ALS 490: EvUp)
Population, Intervention, Comparators and Outcome
 Population: Adults and children in cardiac arrest in any setting (in-
hospital or out-of-hospital) and who have advanced airways in
place
 Intervention: The use of automatic ventilators
 Comparator: Use of manual ventilation
 Outcome: Ventilation, oxygenation, hands-off time, continuous
compressions, survival
 This topic was last reviewed in 2010.6,8 An evidence update is
included in [1876_TD$DIFF]Supplement Appendix C-5. A search restricted to
January 1, 2008, toDecember 7, 2019, identified 1 very small RCT
and 3 observational studies.69  72 An updated SysRev was not
considered necessary.
Treatment Recommendation
This treatment recommendation (below) is unchanged from 2010.6,8
There is insufficient evidence to support or refute the use of an
automatic transport ventilator over manual ventilation during resusci-
tation of the cardiac arrest victim with an advanced airway.
Circulatory Support During CPR
ECPR Versus Manual or Mechanical CPR (ALS 723:
2018 SysRev, 2019 CoSTR)
Extracorporeal CPR (ECPR) was addressed by a 2018 SysRev73 and
a 2019 published CoSTR summary.2,3 Consensus on Science,
Values, Preferences, and Task Force Insights and Knowledge Gaps
can be found in the 2019 CoSTR summary.2,3
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults (18 years or older) and children (younger than
18 years) with cardiac arrest in any setting (in-hospital or out-of-
hospital)
 Intervention: ECPR, including extracorporeal membrane oxygen-
ation or cardiopulmonary bypass, during cardiac arrest
 Comparator: Manual CPR and/or mechanical CPR
 Outcome: Short-term survival and neurological outcomes (eg,
hospital discharge, 28 days, 30 days, and 1month) and long-term
survival and neurological outcomes (eg, 3 months, 6 months, and
1 year)
 Study design: Randomized trials, non-RCTs, and observational
studies (cohort studies and case-control studies) with a control
group were included. Animal studies, ecological studies, case
series, case reports, reviews, abstracts, editorials, comments, and
letters to the editor were not included.
 Time frame: All years and languages were included up to May 22,
2018.
Treatment Recommendations
We suggest that ECPR may be considered as a rescue therapy for
selected patients with cardiac arrest when conventional CPR is failing
in settings in which it can be implemented (weak recommendation,
very low-certainty evidence).2,3
Physiological Monitoring During CPR
The ability to monitor physiological variables and tailor ALS
interventions to the patient’s precise physiological state is appealing
and hence the ongoing interest in this area.
Monitoring Physiological Parameters During CPR (ALS 656:
Adopted From Pediatric Task Force ScopRev)
Rationale for Review
Physiological monitoring during CPR, including measurement of end-
tidal CO2 (ETCO2) and arterial blood pressure among other
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parameters, is growing in popularity. There is limited evidence to-date
on whether use of such parameters improves outcomes. This topic
was last updated in 2015.1,7 A Pediatric Task Force ScopRev of
physiological monitoring during CPR for 2020 also included review of
the adult evidence. The adult portion of the ScopRev was included in
this update.
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults who are in cardiac arrest in any setting (in-
hospital or out-of-hospital)
 Intervention: The use of physiological feedback in regard to CPR
quality (eg, arterial catheter, ETCO2monitoring, [1877_TD$DIFF]SpO2waveforms,
or others)
 Comparator: No use of physiological feedback
 Outcome: Survival with favourable neurological/functional out-
come at discharge, 30 days, 60 days, 180 days, and/or 1 year;
survival only at discharge, 30 days, 60 days, 180 days, and/or
1 year; ROSC
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies). If it is anticipated that there will be insufficient studies
fromwhich to drawa conclusion, case seriesmaybe included. The
minimumnumber of cases for a case series to be includedwas set
by the taskforce at 5. Unpublished studies (eg, conference
abstracts, trial protocols) are excluded.
 Time frame: For Step 1, all languages are included if there is an
English abstract. We searched articles from 2015 onward. For
Step 2, if a SysRev or ScopRev of high quality (as per AMSTAR
2 tool) is identified, the search can be limited to beyonddata and/or
scope of that review.
Summary of Evidence
ETCO2 or Arterial Blood Pressure Monitoring. The ScopRev is
included in [1875_TD$DIFF]Supplement Appendix B-2a and 2b. We identified
1 observational propensity-matched cohort study of adult IHCA by
using data from the AHA Get With the Guidelines-Resuscitation
registry.74 In this study, 3032 physiologically monitored patients
(either by ETCO2 or arterial catheter) were compared with
6064 patients without such monitoring. Those monitored showed a
higher rate of ROSC (OR, 1.22 [95%CI, 1.04; 1.43]) but not survival to
discharge (OR, 1.04 [95%CI, 0.91; 1.18]) nor survival with favourable
neurological outcome. The study did not specifically look at diastolic
blood pressure. Even when an arterial catheter was in place, only
about one third reported using the diastolic blood pressure to guide
their CPR efforts.
Near-Infrared Spectroscopy. The ScopRev is included in [1875_TD$DIFF]Supple-
ment Appendix B-2c. Two SysRevs were identified; the latest was
published in 2018 and comprised studies published before February
2017.TheSysRevs concluded that a higher cerebral oxygensaturation
measured with near-infrared spectroscopy (NIRS) is associated with a
higher chance of ROSC and survival and a lower NIRS is associated
with an increased mortality.75,76 However, there is no consensus on
specific thresholds of cerebral oxygen saturation.75 There was a wide
overlap ofmean ormedian cerebral oxygen saturation values between
patients with and without ROSC, and this was also reflected in the
cohort studies.77  79Only1observational study80 compared the ratesof
ROSC with and without NIRS monitoring and found no difference
between thegroups.All otherstudiescomparedNIRSvalues inpatients
who achieved ROSC with those without ROSC. Many different NIRS
devices with noninterchangeable saturation indices were used across
the studies, complicating comparisons.81 The findings of the observa-
tional studies published since February 2017 correlate with those
published in both SysRevs.
The ScopRev did not suggest the existence of sufficient new data
to proceed to a SysRev.
Task Force Insights
Physiological monitoring during CPR is increasingly popular and
potentially useful for both outcome prediction and real-time improve-
ment in CPR quality. The heterogeneity and observational nature of
available studies continues to limit the task force’s ability to make
specific recommendations. The 2015 treatment recommendation is
therefore unchanged.1,7
Treatment Recommendation
This treatment recommendation (below) is unchanged from 2015.1,7
We make no treatment recommendation for any particular
physiological measure to guide CPR because the available evidence
would make any estimate of effect speculative.
Drugs During CPR, Including Timing of
Administration
Since the 2015CoSTR, there have beenRCTs of antiarrhythmics and
vasopressors during CPR82,83 and subsequent publications compar-
ing the intravenous (IV) and intraosseous (IO) route for drugs.84,85
Vasopressors During Cardiac Arrest (ALS 788, 659, 789, 784,
778: 2019 SysRev, 2019 CoSTR)
The topic of vasopressors during cardiac arrest was addressed by a
2019 SysRev86 and a published CoSTR summary. Consensus on
science, justification and evidence to decision highlights, and
knowledge gaps can be found in the 2019 CoSTR summary.2,3
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults (older than 18 years) with cardiac arrest in any
setting (in-hospital or out-of-hospital)
 Intervention: Any vasopressor or combination of vasopressors
provided intravenously or intraosseously during CPR
 Comparator: No vasopressor, a different vasopressor, or a
combination of vasopressors provided intravenously or intra-
osseously during CPR
 Outcome: Short-term survival (ROSC and survival to hospital
admission), midterm survival (survival to hospital discharge, 28
days, 30 days, or 1 month), midterm favourable neurological
outcomes (Cerebral Performance Category [CPC] 1  2 or
modified Rankin Scale [mRS] score 0  3 at hospital discharge,
28 days, 30 days, or 1 month), and long-term unfavourable and
poor (mRS score 4  5) neurological outcomes (after 1 month)
 Study design: Randomized trials, nonrandomized trials, and
observational studies (cohort and case-control studies) with a
comparison group were included.
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 Time frame: All years and languageswere included if therewas an
English abstract to November 23, 2018.
Treatment Recommendations
We recommend administration of epinephrine during CPR (strong
recommendation, low to moderate certainty of evidence).
For nonshockable rhythms (pulseless electric activity/asystole),
we recommend administration of epinephrine as soon as feasible
during CPR (strong recommendation, very low-certainty evidence).
For shockable rhythms (VF/pVT), we suggest administration of
epinephrine after initial defibrillation attempts are unsuccessful during
CPR (weak recommendation, very low-certainty evidence).
We suggest against the administration of vasopressin in place of
epinephrine during CPR (weak recommendation, very low-certainty
evidence).
We suggest against the addition of vasopressin to epinephrine
during CPR (weak recommendation, low-certainty evidence).2,3
Additional Task Force Commentary
Concerns have been expressed about epinephrine increasing the
number of survivors with unfavourable neurological outcome in the
PARAMEDIC2 trial (Pre-Hospital Assessment of the Role of
Adrenaline: Measuring the Effectiveness of Drug Administration in
Cardiac Arrest). The opinion of the ALS Task Force, however, is that
any drug that increases the rate of ROSC and survival, but is given
after several minutes of cardiac arrest when some degree of
neurological damage may already have occurred, will likely increase
the number of survivors with both favourable and unfavourable
neurological outcome. Determining the likelihood of favourable or
unfavourable neurological outcome at the time of starting resuscita-
tion is currently not feasible. Therefore, the task force consensus is
that continuing to use a drug that increases survival and focusing
efforts on providing earlier CPR, earlier drug administration, and
improved postresuscitation care for all patients is likely to increase
survival with a favourable neurological outcome.
Antiarrhythmic Drugs for Cardiac Arrest (ALS 428, 493: 2018
SysRev, CoSTR)
This topic was addressed by a 2018 SysRev87 and a published 2018
CoSTR summary.4,5 Consensus on Science, Values and Prefer-
ences, Task Force Insights, and Knowledge Gaps can be found in the
2018 CoSTR summary.4,5
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults and children in cardiac arrest in any setting (in-
hospital or out-of-hospital) and a shockable rhythm at any time
during CPR or immediately after ROSC
 Intervention: Administration (intravenously or intraosseously) of
an antiarrhythmic drug during CPR or immediately (within 1 hour)
after ROSC
 Comparator: Administration of another anti-arrhythmic drug or
placebo or no drug during CPR or immediately after ROSC
 Outcome: Survival to hospital discharge with good neurologic
outcome and survival to hospital discharge were ranked as critical
outcomes. ROSC was ranked as an important outcome. For
antiarrhythmic drugs after ROSC, rearrest was included as an
important outcome.
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) are eligible for inclusion.
 Time frame: All years and languageswere included if therewas an
English abstract; unpublished studies (eg, conference abstracts,
trial protocols) were excluded. The literature search was updated
to August 15, 2017.
Treatment Recommendations
We suggest the use of amiodarone or lidocaine in adults with shock-
refractory VF/pVT (weak recommendation, low certainty evidence).
We suggest against the routine use of magnesium in adults with
shock-refractory VF/pVT (weak recommendation, very low-certainty
evidence).
Theconfidence in effect estimates is currently too low to support an
ALS Task Force recommendation about the use of bretylium,
nifekalant, or sotalol in the treatment of adults in cardiac arrest with
shock refractory VF/pVT.
Theconfidence in effect estimates is currently too low to support an
ALS Task Force recommendation about the use of prophylactic
antiarrhythmic drugs immediately after ROSC in adults with VF/pVT
cardiac arrest.4,5
IV Versus IO Drug Delivery (ALS 2046: SysRev)
Rationale for Review
This is a newALS question that was based on the increasing use of IO
access during adult resuscitation. It can often be difficult to obtain IV
access, especially in the prehospital setting. IO access as an
alternative to IV access is increasingly used during cardiac arrest.
However, whether drugs are as effective when administered intra-
osseously versus intravenously is unknown. This 2020 CoSTR is
informed by a 2020 SysRev.88
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults with cardiac arrest in any setting (in-hospital or
out-of-hospital)
 Intervention: Placement of an IO cannula and drug administration
through this IO during cardiac arrest
 Comparator: Placement of an IV cannula and drug administration
through this IV during cardiac arrest
 Outcome: ROSC, or survival/survival with a favourable neurologi-
cal outcome at hospital discharge, 30 days, or longer
 Study design: Randomized trials, non-RCTs, and observational
studies (cohort studies and case-control studies) comparing IO
with IV administration of drugs were included. Randomized trials
assessing the effect of specific drugs (ie, epinephrine and
amiodarone/lidocaine) in subgroups related to IO versus IV
administrationwerealso included.Ecological studies, caseseries,
case reports, reviews, abstracts, editorials, comments, letters to
the editor, and unpublished studies were not included. Studies
assessing cost-effectiveness were included for a descriptive
summary.
 Time frame: The literature search was performed on September
12, 2019, and updated on December 17, 2019, with no date
restrictions.
 PROSPERO Registration: CRD42020150877
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Consensus on Science
For the important outcome of ROSC, we identified very low-certainty
evidence (downgraded for risk of bias and inconsistency) from 4
observational studies89  92 including 70 419 adults with OHCA,
demonstrating an association of worse outcomes with the use of IO
access when compared with IV access (adjusted OR, 0.72 [95% CI,
0.68  0.76]; P< 0.00001; absolute risk difference,   6.1% [95% CI,
  7.1 to   5.2] or 61 fewer per 1000 cardiac arrests had ROSC with
IO access compared with IV access [95% CI, 71 fewer to 52 fewer]).
For the critical outcome of survival to hospital discharge, we
identified very low-certainty evidence (downgraded for risk of bias and
inconsistency) from 4 observational studies89  92 including 70 419
adult OHCAs, demonstrating an association of worse outcomes with
the use of IO access when compared with IV access (adjusted OR,
0.71 [95% CI, 0.63  0.79]; P< 0.00001; absolute risk difference,
  2.0% [95% CI,   2.5 to   1.4] or 20 fewer per 1000 cardiac arrests
with survival to hospital discharge with use of IO access compared
with IV access [95% CI, 25 fewer to 14 fewer]).
For the critical outcome of survival to hospital discharge with a
favourable neurological outcome, we identified very low-certainty
evidence (downgraded for risk of bias and inconsistency) from
3 observational studies89,91,92 including 68 619 adult OHCAs,
demonstrating an association of worse outcomes with the use of IO
access when compared with IV access (adjusted OR, 0.60 [95% CI,
0.52  0.69]; P< 0.00001; absolute risk difference,   1.9% [95% CI,
  2.3 to   1.5] or 19 fewer per 1000 cardiac arrests with survival to
hospital discharge with a favourable neurological outcomewith use of
IO access compared with IV access [95% CI, 23 fewer to 15 fewer]).
In addition to these findings from observational studies, we
identified 2 RCTs of drug administration during cardiac arrest that
performed subgroup analyses according to IO versus IV route of
administration.84,85 None of the comparisons showed statistically
significant effect modification. The point estimates generally favored
IV access as compared with IO access, except for the outcome of
ROSC in the PARAMEDIC2 trial where the effect of epinephrine was
similar when given IV or IO. These 2 trials were underpowered to
assess such interactions for any outcomes other than ROSC.
Treatment Recommendations
Wesuggest IV access as comparedwith IO access as the first attempt
for drug administration during adult cardiac arrest (weak recommen-
dation, very low-certainty evidence).
If attempts at IV access are unsuccessful or IV access is not
feasible, we suggest IO access as a route for drug administration
during adult cardiac arrest (weak recommendation, very low-certainty
evidence).
Justification and Evidence-to-Decision Framework Highlights
The evidence-to-decision table is included in [1875_TD$DIFF]Supplement
Appendix A-2. Although the overall certainty in the evidence is very
low, thecurrent evidencesuggests that outcomesmightbebetterwith IV
versus IOdrugadministration.The task forcediscussed thepossibility of
unaccounted-for confounders in comparing patients for whom an IV
couldbeobtainedwith thosewho required IOplacement for access.The
task force also discussed that 2015 council guidelines suggest that IO
access should be used only if IV access is “difficult or impossible”17 or
“not readily available.”93 The included studies did not enablemeaningful
analyses of specific subgroups. The documented IO site was primarily
tibial, but thesitewasoftennotdocumented.Assuch,nostatementscan
bemade about difference between tibial and humeral (or other) IO sites.
All studies were conducted in OHCA patients. Although IHCA patients
are likely to have existing IV access, this is not universally true. Although
there might be differences in provider skills and patient characteristics
betweenOHCA and IHCA, we consider it unlikely that these would lead
to substantial effectmodification. As such, the above recommendations
apply to both IHCA and OHCA.
Knowledge Gap
 The overall certainty in the evidence is very low. As such, there is
clinical equipoise for additional trials related to IV versus IO drug
administration during cardiac arrest. These could include trials
that directly compare IV to different sites of IO access (eg, tibial,
humeral).
Steroids During CPR (ALS 433: EvUp)
Population, Intervention, Comparator, and Outcome
 Population: Adults who are in cardiac arrest in any setting (in-
hospital or out-of-hospital)
 Intervention: Corticosteroid or mineralocorticoid administration
during CPR
 Comparator: Not using steroids
 Outcome: Survival with favourable neurological/functional out-
come at discharge, 30 days, 60 days, 180 days, and/or 1 year;
survival only at discharge, 30 days, 60 days, 180 days, and/or
1 year; ROSC
 Intra-arrest steroid usewas last reviewed in 2015.1,7 The EvUp for
intra-arrest steroid use is included in [1876_TD$DIFF]Supplement Appendix C-6.
The search identified 2 large, population-based observational
studies published since the 2015 CoSTR,94,95 both of which
suggest a possible association between the use of corticosteroids
duringCPR and improved survival. Three ongoing clinical trials on
this topic were also identified (NCT02790788, NCT03640949,
NCT03317197). The task force will prioritize a SysRev when the
results of these trials become available.
Treatment Recommendation
This treatment recommendation (below) is unchanged from 2015.1,7
For IHCA, the task force was unable to reach a consensus
recommendation foror against theuseof steroidsduringcardiacarrest.
We suggest against the routine use of steroids during CPR for
OHCA (weak recommendation, very low-certainty evidence).
Buffering Agents for Cardiac Arrest (ALS 483: EvUp)
Population, Intervention, Comparator, and Outcome
 Population: Adults with cardiac arrest in any setting (in-hospital or
out-of-hospital)
 Intervention: The use of buffering agents alone or combination
with other drugs
 Comparator: Not using drugs (or a standard drug regimen)
 Outcome: ROSC, survival, survival with favourable neurological
outcome
 This topic was last reviewed in 2010.6,8 An EvUp was completed
for 2020 and is included in [1876_TD$DIFF]Supplement Appendix C-7. One small
RCT and 4 observational studies were identified.96  100 An
updated SysRev was not considered necessary.
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Treatment Recommendation
This treatment recommendation (below) is unchanged from 2010.6,8
Routine administration of sodium bicarbonate for treatment of
IHCA and OHCA is not recommended.
Drugs for Torsades de Pointes (ALS 457: EvUp)
Population, Intervention, Comparator, and Outcome
 Population: Adults with torsades de pointes in any setting (in-
hospital or out-of-hospital)
 Intervention: Any drug or combination of drugs
 Comparator: Not using drugs or alternative drugs
 Outcome:ROSC, survival, or survivalwith favourable neurological
outcome
 This PICO was last reviewed in 2010.6,8 An EvUp is included in [1876_TD$DIFF]
Supplement Appendix C-8. No studies meeting inclusion criteria
were identified, and thus consideration of an updated SysRevwas
not suggested.
Treatment Recommendation
This treatment recommendation (below) is unchanged from 2010.6,8
Polymorphic wide-complex tachycardia associated with familial
long QT may be treated with IV magnesium, pacing, and/or beta
blockers; however, isoprenaline should be avoided.
Polymorphic wide-complex tachycardia associated with acquired
long QT may be treated with IV magnesium.
Addition of pacing or IV isoprenaline may be considered when
polymorphic wide-complex tachycardia is accompanied by bradycar-
dia or appears to be precipitated by pauses in rhythm.
Intra-arrest Prognostication
Point-of-Care Echocardiography for Prognostication During
CPR (ALS 658: SysRev)
Rationale for Review
In 2015, the question of whether the use of cardiac ultrasound during
CPR changed outcomeswas reviewed.1,7 This question has not been
reviewed for the 2020 CoSTR for ALS, and the 2015 CoSTR currently
remains: We suggest that if cardiac ultrasound can be performed
without interfering with standard advanced cardiovascular life support
protocols, it may be considered as an additional diagnostic tool to
identify potentially reversible causes (weak recommendation, very
low-quality evidence).1,7
The current question is different from that mentioned above and
was prioritized by the ALS Task Force due to the increasing
popularity of the use of point-of-care echocardiography during
cardiac arrest as a prognostic tool, as well as concern about
potential pitfalls for misinterpretation of ultrasound findings. A task
force  led SysRev of the intra-arrest prognostic capabilities of point-
of-care echocardiography was performed to inform the 2020 CoSTR
for ALS.101
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults with cardiac arrest in any setting (in-hospital or
out-of-hospital).
 Intervention: A particular finding on point-of-care echocardiogra-
phy during CPR
 Comparator: The absence of that finding or a different finding on
point-of-care echocardiography during CPR
 Outcome:Clinical outcomes include, but are not necessarily limited
to, ROSC, survival to hospital admission, (both important) and the
critical outcomes of survival/survival with a favourable neurological
outcome at hospital discharge, and survival/survival with a
favourable neurological outcome beyond hospital discharge.
 Study design: Randomized trials, non-RCTs, observational
studies (cohort studies and case-control studies), registries,
and prognosis studies. Ecological studies, case series, case
reports, reviews, abstracts, editorials, comments, letters to the
editor, or unpublished studies will not be included.
 Time frame: All years and languageswere included if therewas an
English abstract, and therewerenodate restrictions. The literature
search was updated to September 18, 2019.
[1878_TD$DIFF] PROSPERO Registration: CRD42020150677.
[1879_TD$DIFF]Consensus on Science
The SysRev identified no RCTs and 15 relevant observational
studies.102  116 The overall certainty of evidencewas rated as very low
for all outcomes primarily due to risk of bias, inconsistency, and/or
imprecision. There was a substantial risk of bias due to prognostic
factor measurement, outcome measurement, adjustment for prog-
nostic factors, or confounding. Because of this and a high degree of
clinical heterogeneity, no meta-analyses could be performed, and
individual studies are difficult to interpret. Theconsensus on science is
summarized in Table 1. The summary of each outcome is separated
by the ultrasonographic finding (organized contractility versus non-
organized and/or unspecified motion) and timing of image acquisition
(initial, every, any, or subsequent evaluation; or unspecified) because
these also varied considerably across studies.
Treatment Recommendation
We suggest against the use of point-of-care echocardiography for
prognostication during CPR (weak recommendation, very low-
certainty evidence)
Justification and Evidence-to-Decision Framework Highlights
The evidence-to-decision table is included in [1875_TD$DIFF]Supplement
Appendix A-3. This CoSTR specifically addresses the role of
ultrasound in prognostication, and in particular prognostication of a
favourable outcome that is based on the presence of cardiac motion.
In 2015, the task force stated that ultrasound had a potential role in
diagnosing reversible causes of cardiac arrest if it could be done
without interfering with high-quality CPR, and this recommendation
was not reassessed for 2020.1,7
Given the increasing popularity of the use of point-of-care
echocardiography for prognostication during attempted resuscitation
aftercardiacarrest, thiscomprehensiveandrigoroussummaryof its intra-
arrest prognostic capabilities provides valuable information to both the
resuscitation sciencecommunity andbedside clinicians. Inmaking these
recommendations, the ALS Task Force considered the following:
There were inconsistent definitions and terminology about the
sonographic evidence of cardiac motion. This included wide variation
in the classification of anatomy, type of motion, and timing of point-of-
careechocardiogram.The task forceencourages theestablishmentof
uniform definitions and terminology to describe sonographic findings
of cardiac activity during cardiac arrest.
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Table1 –EstimatedPrognosticTestPerformanceandPrognosticAssociation forSonographicFindingsonPoint-of-
Care Echocardiography During Cardiac Arrest to Predict Clinical Outcomes.
Outcome Author, Year Total Subjects (n),
IHCA or OHCA
Sensitivity
(Range or 95% CI)
Specificity
(Range or 95% CI)
Odds Ratio
(Range or 95% CI)
Organized Cardiac Motion (Unspecified Timing of Echocardiography)
Survival 180 days Flato, 2015113 49, IHCA 1.0 (95% CI, 0.4  1.0) 0.49 (95% CI, 0.34
  0.64)
8.62 (95% CI, 0.44
  169.38)
Survival to hospital discharge Atkinson, 2019108
Flato, 2015113
229, IHCA and OHCA 0.67  1.00 0.51  0.89 13.60  16.63
Survival to hospital admission Atkinson, 2019108
Blaivas, 2001109
349, OHCA 0.39  1.00 0.91  0.91 6.73  414.56
ROSC Atkinson, 2019108
Flato, 2015113
229, IHCA and OHCA 0.34  0.79 0.68  0.96 8.07  13.21
Nonorganized and/or Unspecified Cardiac Motion on Initial Echocardiogram
Good neurological outcome at
discharge
Aichinger, 2012107 42, OHCA 1.00 (95% CI, 0.03
  1.00)
0.78 (95% CI, 0.62
  0.89)
10.26 (95% CI, 0.39
  273.09)
Survival to hospital discharge Gaspari, 2016114
Varriale, 1997106
Zengin, 2016116
1171, y IHCA and
OHCA
0.06  0.91 0.49  0.94 0.38  17.00








861, IHCA and OHCA 0.25  0.64 0.78  1.00 6.33  16.11
[1865_TD$DIFF]Nonorganized and/or Unspecified Cardiac Motion on Every Echocardiogram
Survival to hospital admission Aichinger, 2012107
Salen, 2001104
134,* OHCA 0.50  0.80 0.92  1.00 45.33  148.20
[1866_TD$DIFF]Nonorganized and/or Unspecified Cardiac Motion (Unspecified Timing of Echocardiography)
Good neurological outcome at 180
days
Flato, 2015113 49, IHCA 1.00 (95% CI, 0.40
  1.00)
0.49 (95% CI, 0.34
  0.64)
8.62 (95% CI, 0.44
  169.38)
Good neurological outcome at
discharge
Salen, 2005103 70, OHCA 1.00 (95% CI, 0.03
  1.00)
0.86 (95% CI, 0.75
  0.93)
17.00 (95% CI, 0.65
  446.02)
Survival to hospital discharge Lien, 2018102 177, OHCA 0.48 (95% CI, 0.28
  0.69)
0.77 (95% CI, 0.69
  0.83)
3.09 (95% CI, 1.29
  7.37)
Survival to hospital admission Breitkreutz, 2010110
Chua, 2017112
Salen, 2001104





317, OHCA 0.62  1.00 0.33  0.98 23.18  289.00
[1867_TD$DIFF]Return of Organized Cardiac Motion on Subsequent Echocardiogram
Survival to hospital discharge Varriale, 1997106 20, IHCA 0.50 (95% CI, 0.01
  0.99)
0.79 (95% CI, 0.54
  0.94)
3.75 (95% CI, 0.19
  74.06)
ROSC Varriale, 1997106 20, IHCA 0.67 (95% CI, 0.22
  0.96)
1.00 (95% CI, 0.77
  1.00)
52.50 (95% CI, 2.10
  1300.33)
[1868_TD$DIFF]Coalescent Echo Contrast (ie, Visible Clotted Intra-Cardiac Blood) After 20  30 min of CPR
Survival to hospital discharge Varriale, 1997106 20, IHCA 0.00 (95% CI, 0.00
  0.84)
0.45 (95% CI, 0.23
  0.68)
0.13 (95% CI, 0.01
  3.11)
ROSC Varriale, 1997106 20, IHCA 0.00 (95% CI, 0.00
  0.46)
0.21 (95% CI, 0.05
  0.51)
0.02 (95% CI, 0.00
  0.53)
[1869_TD$DIFF]Sonographic Evidence of Treatable Pathology
Survival to hospital discharge Gaspari, 2016114
Varriale, 1997106
Zengin, 2016116
1130,y IHCAandOHCA 0.00  0.15 0.89  0.98 1.32  4.25





317,y IHCA and OHCA 0.00  1.00 0.84  0.94 0.38  125.00
IHCA indicates in-hospital cardiac arrest; OHCA, out-of-hospital cardiac arrest; and ROSC, return of spontaneous circulation.
* Studies did not report these data for all enrolled subjects; n is lower than the total of all subjects enrolled.
y Gaspari et al and Zengin et al report multiple sonographic findings within a given category on the same subjects; n reflects composite variable “subject-
assessments[1870_TD$DIFF]”.
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Most of the identified studies suffer from high risk of bias related to
prognostic factor measurement, outcome measurement, lack of
adjustment for other prognostic factors, and confounding from self-
fulfilling prophecy and unspecified timing of point-of-care echocardi-
ography. Because the risk of bias and heterogeneity across studies
was high, no meta-analyses were performed. The evidence support-
ing use of point-of-care echocardiography as a prognostic tool during
cardiac arrest is uniformly of very low certainty. Clinicians should
interpret sonographic findings during cardiac arrest in light of these
limitations. The task force encourages subsequent investigators
studying point-of-care echocardiography during cardiac arrest to
identify methodology that mitigates these risks of bias.
Only 2 studies113,114 reported estimates of inter-rater reliability
(Kappa 0.63 and 0.93). More uniform reporting of inter-rater reliability
of point-of-care echocardiography interpretation in future investiga-
tions is important.
No sonographic finding had sufficient and/or consistent sensitivity
for any clinical outcome for its absence to be used as a sole criterion to
stop resuscitation, but the certainty of this evidence is very low.
Some sonographic findings had higher ranges of specificity for
clinical outcomes, but the certainty of this evidence is very low.
The impact of ECPR on the prognostic accuracy of point-of-care
echocardiography is uncertain.
Point-of-care echocardiography may still be useful to diagnose
treatable etiologies of cardiac arrest or to intermittently assess
response to resuscitative treatments. These applications are not
within the scope of this particular PICOST question. We do, however,
caution against overinterpreting the finding of right-ventricular dilation
in isolation as a diagnostic indicator of massive pulmonary embolism.
Right-ventricular dilation begins a few minutes after onset of cardiac
arrest as blood shifts from the systemic circulation to the right heart
along a pressure gradient.117,118 Right-ventricular dilation was
uniformly observed in a porcine model of cardiac arrest across
etiologies of hypovolemia, hyperkalemia, and primary arrhythmia.119
Clinicians should be cautious about potentially prolonging
interruptions in chest compressions when using point-of-care
echocardiography during cardiac arrest.120,121 Several strategies to
minimize these interruptions have been proposed.122,123
Point-of-care echocardiography is subject to availability of
equipment and skilled operators.
Knowledge Gaps
 There is no standardized or uniform definition of cardiac motion
visualized on point-of-care echocardiography during cardiac
arrest.
 There are very few prognostic factor studies of point-of-care
echocardiography during cardiac arrest performed with method-
ology that minimizes risk of bias.
 The inter-rater reliability of point-of-care echocardiography during
cardiac arrest is uncertain.
 The relative roles and feasibility of transesophageal versus
transthoracic echocardiography during CPR require research.
ETCO2 to Predict Outcome of Cardiac Arrest (ALS 459: EvUp)
Population, Intervention, Comparator, and Outcome
 Population: Adults who are in cardiac arrest in any setting (in-
hospital or out-of-hospital)
 Intervention: Any ETCO2 level value, when present
 Comparator: Any ETCO2 level below that value
 Outcome: ROSC, survival, survival with favourable neurological
outcome
 This topicwas last updated in a published 2015CoSTR,1,7 and the
SysRev that informed thisCoSTRwaspublished in 2018.124 The2
EvUps are included in [1876_TD$DIFF]Supplement Appendix C-9a and C-9b. A
search from December 2013 to November 2019 identified 7 new
observational studies74,80,125  129 in addition to the previous
SysRev.124 The task force discussed the low likelihood of an
updated SysRev leading to a change in treatment recommenda-
tions based on the available studies, and therefore did not
prioritize this topic for a SysRev at this time. Future studies and
SysRevs should consider trends and changes in ETCO2 values
during CPR in addition to the significance of single ETCO2 values.
The 2015 treatment recommendations remain unchanged.1,7
Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.1,7
We recommend against using ETCO2 cutoff values alone as a
mortality predictor or for the decision to stop a resuscitation attempt
(strong recommendation, low-quality evidence).
We suggest that anETCO2 of 10mmHgor greatermeasured after
tracheal intubation or after 20minutes of resuscitation may be a
predictor of ROSC (weak recommendation, low-quality evidence).
We suggest that anETCO2 of 10mmHgor greatermeasured after
tracheal intubation, or an ETCO2 of 20mm Hg or greater measured
after 20minutes of resuscitation, may be a predictor of survival to
discharge (weak recommendation, moderate-quality evidence).
Cardiac Arrest in Special Circumstances
Cardiac Arrest Associated With Pulmonary Embolism (ALS
435, 581: SysRev)
Rationale for Review
Pulmonary embolism (PE) is a potentially reversible cause of cardiac
arrest. Whether chances for ROSC and survival may be significantly
higher if a PE is present and can be treated is not well established
because research has been limited to-date. This topic was last
reviewed in 2015.1,7 The specific role of ECPR was not addressed in
this updated SysRev because ECPR was addressed in the previous
2019 CoSTR summary.2,3 The role of ECPR for the treatment of PE
and cardiac arrest is discussed in the justification section that follows.
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults in cardiac arrest due to PE or suspected PE in
any setting (in-hospital or out-of-hospital)
 Intervention: Any specific alteration in theALS treatment algorithm
(eg, fibrinolytics or any other)
 Comparator: Standard ALS care
 Outcome: Survival with favourable neurological outcome at
discharge, 30 days, 60 days, 180 days, and/or 1 year; survival
at discharge, 30 days, 60 days, 180 days, and/or 1 year (all
critical); ROSC (important)
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
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studies) are eligible for inclusion. Unpublished studies (eg,
conference abstracts, trial protocols) are excluded.
 Time frame: All years and languageswere included if therewas an
English abstract. Literature search was updated to October 2019.
 PROSPERO Registration: Registered with ILCOR Science
Advisory Committee October 6, 2019. This SysRev was done
as an update of the 2015 CoSTR SysRev and PROSPERO
registration was not done.
Consensus on Science
Fibrinolysis. For the critical outcome of survival with favourable
neurological outcome at 30 days, we identified very low-certainty
evidence (downgraded for serious imprecision and very serious risk of
bias) from a subgroup of 37 patients with confirmed PE from 1 RCT
comparing fibrinolyticswithplaceboduring cardiac arrest130 findingno
difference between groups [tenecteplase 2/15, (13.3%) versus
placebo, 0/22 (0%)] [risk ratio (RR), 7.19; 95% CI, 0.37  139.9].
We also identified very low-certainty evidence (downgraded for risk of
bias) from a single observational study that found no difference (10%
with fibrinolysis versus 5%without; adjusted RR [ARR], 1.97; 95%CI,
0.70  5.56).131
For the critical outcome of survival at 30 days, very low-certainty
evidence (downgraded for risk of bias) from one observational study
showed an association between improved survival and administration
of fibrinolysis (16% with fibrinolysis versus 6% without; P=0.005).131
For the critical outcome of survival to hospital discharge, very low-
certainty evidence (downgraded for very serious risk of bias and
imprecision) from 3 retrospective observational studies showed no
association between administration of fibrinolysis and survival (10.5%
survival with fibrinolysis versus 8.7% without;132 9.5% survival with
fibrinolysis versus 4.8%without133 and19.4%survival with fibrinolysis
versus 6.7% without (RR, 2.9; 95% CI, 0.75  13.8).134
For the important outcome of ROSC, very low-certainty evidence
from1 study (downgraded for very serious risk of bias) showed benefit
associated with the use of fibrinolytic drugs compared with no
fibrinolytic drugs in patients with PE (81.0% with fibrinolysis versus
42.9% without; P=0.03).133 Two other studies provided very low-
certainty evidence (downgraded for very serious risk of bias) of no
difference inROSC (66.7%with fibrinolysis versus43.3%without [RR,
1.5; 95% CI, 0.8  8.6] and 47.4% with fibrinolysis versus 47.8%
without; P=0.98).132,134
For the outcome of survival at 24 hours, very low-certainty
evidence (downgraded for risk of bias) from 1 observational study
showed no difference associated with fibrinolysis (66% with fibrinoly-
sis versus 63% without; P=0.76),131 whereas another study showed
benefit associated with fibrinolysis (52.8% with fibrinolysis versus
23.3% without; RR, 2.3; 95% CI, 1.1  4.7).134
Surgical Embolectomy. We found very low-certainty evidence
(downgraded for very serious risk of bias) from 2 case series135,136
with no control groups and a total of 21 patients requiring CPR with a
30-day survival rate of 12.5% and 71.4%, respectively.
Percutaneous Mechanical Thrombectomy. For the important
outcome of ROSC, very low-certainty evidence (downgraded for
very serious risk of bias and very serious imprecision) from 1 case
series of 7 patients with cardiac arrest with no control group,137 ROSC
was achieved in 6 of 7 patients (85.7%) treated with percutaneous
mechanical thrombectomy.
The overall certainty of evidence was rated as very low primarily
due to a very serious risk of bias and inconsistency. For this reason, no
meta-analyses were performed.
Treatment Recommendations
These recommendations (below) are unchanged from 2015.1,7 We
suggest administering fibrinolytic drugs for cardiac arrest when PE is
the suspected cause of cardiac arrest (weak recommendation, very
low-certainty evidence).
Wesuggest theuseof fibrinolytic drugsor surgical embolectomyor
percutaneous mechanical thrombectomy for cardiac arrest when PE
is the knowncauseof cardiac arrest (weak recommendation, very low-
certainty evidence).
Justification and Evidence-to-Decision Framework Highlights
The evidence-to-decision table is included in [1875_TD$DIFF]Supplement
Appendix A-4. The task force considered that mechanical or surgical
thrombectomy would be used only if the patient had a confirmed PE.
No RCTs were identified and no meta-analysis was undertaken given
the limited evidence.
The task forceconsidered that2%to7%ofpatientswithOHCAhave
aPE,130,131and this figure isprobablyhigher forpatientswith IHCA.The
task force acknowledged that ECPR techniques are now frequently
used in patientswith cardiac arrest fromsuspectedPE in those settings
where it is feasible. This role of ECPR for advanced life support was
addressed by the 2019 CoSTR summary, and the considered studies
includedpatientswithPE.2,3Specifically inpatientswithPE,ECPRmay
potentially facilitate the use of fibrinolysis or mechanical or surgical
embolectomy, but the evidence is of very low certainty.
The task force considered the increased risk of bleeding from
fibrinolysis if it is administered topatientswithoutPE.TheThrombolysis
in Cardiac Arrest (TROICA) Study—which is the largest study of
thrombolysis during cardiac arrest—showed an increased risk of
bleeding in the thrombolysis group (any intracranial hemorrhage, 2.7%
versus 0.4%; RR, 6.95 [95% CI, 1.59  30.41]; P=0.006), but major
bleeding complications did not occur more often (symptomatic
intracranial hemorrhage, 0.8% versus 0%; RR, 8.93 [95% CI, 0.48
  165.45]; P=0.13; major nonintracranial hemorrhage, 7.7% versus
6.4; RR, 1.21 [95% CI, 0.77  1.88]; P=0.48; ischemic stroke, 0.8%
versus 0.6%; RR, 1.32 [95% CI, 0.30  5.88]; P=1.00).130 Patients are
far more likely to die from the cardiac arrest than from the treatment.
Knowledge Gap
 Optimal drug and dosing strategy for fibrinolysis duringCPRwith a
suspected or actual PE
 Intra-arrest prediction of PE during CPR
Cardiac Arrest in Pregnancy (ALS 436: EvUp)
Population, Intervention, Comparator, and Outcome
 Population:Pregnantwomenwhoare incardiacarrest inanysetting
 Intervention: Any specific intervention(s)
 Comparator: Standard care (usual resuscitation practice)
 Outcome: ROSC; survival to discharge, 30 days, or longer;
survival with favourable neurological outcome at discharge, 30
days, or longer
 An EvUp is included in [1876_TD$DIFF]Supplement Appendix C-10. Since the
2015CoSTR,1,7 7 newsmall observational studieswere identified,
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5 of which focused on association of timing of delivery with
outcome of cardiac arrest and other factors associated with
maternal and fetal mortality.138  142 Due to the very small size of
most studies, an updated SysRev was not suggested. The 2015
treatment recommendation remains unchanged.1,7
Treatment Recommendation
This treatment recommendation (below) is unchanged from 2015.1,7
We suggest delivery of the fetus by perimortem cesarean delivery
for women in cardiac arrest in the second half of pregnancy (weak
recommendation, very low-quality evidence).
There is insufficient evidence to define a specific time interval by
which delivery should begin.
High-quality usual resuscitation care and therapeutic interventions
that target the most likely cause(s) of cardiac arrest remain important
in this population.
There is insufficient evidence to make a recommendation about
the use of left-lateral tilt and/or uterine displacement duringCPR in the
pregnant patient.
Opioid Toxicity (ALS 441: EvUp)
Death from opioid toxicity is an important public health issue in many
countries. The issue of first aid education for opioid toxicity has been
addressed by the EIT Task Force ScopRev 891.142a,142b
Population, Intervention, Comparator, and Outcome
 Population: Adults who are in cardiac arrest or respiratory arrest
due to opioid toxicity in any setting (in-hospital or out-of-hospital)
 Intervention: Any specific therapy (eg, naloxone, bicarbonate, or
other drugs)
 Comparator: Usual ALS care
 Outcome: Survival with favourable neurological/functional
outcome at discharge, 30 days, 60 days, 180 days, and/or
1 year; survival only at discharge, 30 days, 60 days, 180 days,
and/or 1 year; ROSC were defined as critical or important
outcomes
 This topic was last reviewed in 2015.1,7 The EvUp is included in [1876_TD$DIFF]
Supplement Appendix C-11. The search was conducted for
studiespublished fromSeptember 1, 2013 toSeptember 13, 2019.
There was insufficient evidence to support consideration of a
stand-alone ALS SysRev, but an updated SysRev with other task
forces was suggested.
Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.1,7
We recommend the use of naloxone by IV, intramuscular,
subcutaneous, IO, or intranasal routes in respiratory arrest associated
with opioid toxicity (strong recommendation, very low-quality
evidence). The dose of naloxone required will depend on the route.
We can make no recommendation about the modification of
standard ALS in opioid-induced cardiac arrest.
Postresuscitation Care
The last update of postresuscitation care was published in the 2015
CoSTR.1,7 Since that publication, there have been many reported
studies of postresuscitation care.143
Oxygen Dose After ROSC in Adults (ALS 448: SysRev)
Rationale for Review
Both hypoxemia and hyperoxemia during postresuscitation care have
been associated with worse outcomes. Hypoxemia may worsen
ischemic brain injury and injury to other organs, and hyperoxemiamay
lead to increased oxidative stress and organ damage after reperfu-
sion. A SysRevwas conducted to inform this 2020 CoSTR for ALS.144
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Unresponsive adults with sustained ROSC after
cardiac arrest in any setting
 Intervention: A ventilation strategy targeting a specific oxygen
saturation and/or Pao2
 Comparator: Treatment without specific targets or with an
alternate target to the intervention
 Outcome: Critical outcomes include survival/survival with a
favourable neurological outcome at hospital discharge or 30
days; and survival/survival with a favourable neurological
outcome after hospital discharge or 30 days (eg, 90 days, 180
days, 1 year).
 Study design: Randomized trials, non-RCTs, and observational
studies (cohort studies and case-control studies) with a control
group (ie, patients treatedwith no specific oxygen saturation and/or
Pao2 targets or an alternative target to the intervention) were
included. Animal studies, ecological studies, case series, case
reports, reviews, abstracts, editorials, comments, and letters to the
editor were not included. There were no limitations on publication
period or study language, if there was an English abstract. The
population included patients with IHCA or OHCA of any origin.
Unpublishedstudies(eg,conferenceabstracts, trialprotocols)were
excluded. The cited SysRev144 was perfomed without age
restriction, and the evidence from adult studies (generally defined
as older than 16 years or 18 years or older) is included here.
 Time frame: All years and languageswere included. The literature
search was updated to August 22, 2019.
 PROSPERO Registration: CRD42020150877
Consensus on Science
The evidence from the 6RCTs identified in the SysRev is summarized
in Table 2. Trials generally failed to show a benefit of a titrated (lower
percentageof oxygen) approach comparedwith standard care (higher
percentage of oxygen). A subgroup analysis of postresuscitation
patients in one larger RCT, however, found better survival in patients
for whom hyperoxemia was aggressively avoided.145 In addition,
results from 10 observational studies rated as having only serious risk
of bias were inconsistent. Four146  149 found an association between
hyperoxemia (variable definitions, but most often PaO2 greater than
300mm Hg) and either worse survival or worse survival with
neurological outcome, whereas the other 6150  155 found no such
association. Hypoxemia was found to be associated with worse
outcome in adjusted analysis in 1 of these studies.149
Treatment Recommendations
We suggest the use of 100% inspired oxygen until the arterial oxygen
saturation or the partial pressure of arterial oxygen can be measured
reliably in adults with ROSC after cardiac arrest in any setting (weak
recommendation, very low-certainty evidence).
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We recommend avoiding hypoxemia in adults with ROSC after
cardiac arrest in any setting (strong recommendation, very low-
certainty evidence).
We suggest avoiding hyperoxemia in adults with ROSCafter cardiac
arrest in any setting (weak recommendation, low-certainty evidence).
Justification and Evidence-to-Decision Framework Highlights
Theevidence-to-decision table is included in [1875_TD$DIFF]SupplementAppendixA-5.
In making the recommendation to avoid hypoxemia, the task force
acknowledges that the evidence is of very low certainty. The task force
concluded that the known harm that can result from hypoxia justifies its
avoidance, and detection of hypoxemiamay be the best surrogate for or
precursor of tissue hypoxia. The suggestion to avoid hyperoxemia is
based on low- to moderate-certainty evidence that showed either harm
or no benefit from hyperoxemia. The definitions used for hyperoxemia
varied, ranging from an oxygen saturation greater than 97% measured
by pulse oximeter to a PaO2 up to 20 to 25kPa (150  188mmHg) in the
available RCTs. In light of the possible benefit and lack of evidence for
harm, the task force suggests targeting normoxemia and avoiding
hyperoxemia.The task forceacknowledges that theprimary randomized
trial evidence suggesting benefit from avoiding hyperoxemia is from a
subgroup analysis only, and data from the 3 ongoing trials
(NCT03138005, NCT03653325, NCT03141099) will be helpful.
The task force felt that titration of oxygen should not be
attempted until oxygen levels (peripheral oxygen saturation or
partial pressure of oxygen in arterial blood) could be measured
reliably. Some of the randomized trials conducted in the prehospital
setting, although very small, reported more desaturation of arterial
blood in the lower oxygen group, which reinforces the task force
suggestion to administer 100% oxygen until reliable measurement
of oxygen level is possible. This is likely to be more important in the
prehospital setting.
Knowledge Gap
 Randomized trials comparing lower oxygen target strategies with
higher oxygen target strategies or usual care in postarrest patients
have thus far been small and therefore inconclusive. More trials
are needed, and 3 trials are underway currently (NCT03138005,
NCT03653325, NCT03141099).
Table 2 – Overview of Included Randomized Trials [1871_TD$DIFF]of Oxygen Dose after ROSC.










Favourable Neurological Outcome at 6 mo*—ICU Initiation
Jakkula, 2018156 Finland and
Denmark
2016  2017 120 Normoxia for 36 h
(10  15 kPa)
Moderate hyperox-
ia for 36 h (20
  25 kPa)
1.13 [0.87  1.47] 79 more per 1000
[79 fewer to 287
more]
Moderatey
Mackle, 2019145 Australia and
New Zealand
2015  2018 164 Conservative oxy-




1.40 [0.93  2.13] 128 more per 1000
[22 fewer to 361
more]
Very lowz
Survival to Hospital Discharge With Favourable Neurological Outcome#—Prehospital Initiation
Young, 2014157 New Zealand 2012  2013 17 Titrated oxygen for
72 h (O2 Sat 90%
  94%)
Standard oxygen
for 72 h (O2 Sat
>95%)
0.56 [0.14  2.29] 196 fewer per 1000
[382 fewer to 573
more]
Very low{




1.33 [0.63  2.84] 141 more per 1000
[159 fewer to 789
more]
Lowx
Survival to Hospital Discharge—ICU Initiation
Jakkula, 2018156 Finland and
Denmark
2016  2017 120 Normoxia for 36 h
(10  15 kPa)
Moderate hyperox-
ia for 36 h (20
  25 kPa)
1.07 [0.84  1.36] 46 more per 1000
[106 fewer to 238
more]
Moderatex
Survival to 90 Days—ICU Initiation
Mackle, 2019145 Australia and
New Zealand
2015  2018 164 Conservative oxy-




1.39 [1.01  1.92] 160 more per 1000
[4 more to 377
more]
Lowyy








89 Low oxygen pre-





0.97 [0.68  1.37] 18 fewer per 1000
[194 fewer to 224
more]
Very lowx






3.15 [1.04  9.52] 379 more per 1000





New Zealand 2012  2013 17 Titrated oxygen for
72 h (O2 Sat 90%
  94%)
Standard oxygen
for 72 h (O2 Sat
>95%)
1.13 [0.41  3.08] 58 more per 1000
[262 fewer to 924
more]
Very low{
ICU indicates intensive care unit; Sat, saturation.
* Defined as either Cerebral Performance Category (CPC) 1  2 or Extended Glasgow Outcome Score of 5  8.
y Downgraded for imprecision.
z Downgraded for risk of bias and imprecision.
x Downgraded 2 levels for imprecision.
{ Downgraded for indirectness and 2 levels for imprecision.
# Defined as CPC 1  2 or discharge to home.
** Intervention initiated prehospital but continued after admission.
yyDowngraded 2 levels for risk of bias.
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Ventilation Strategy After ROSC in Adults (ALS 571: SysRev)
Rationale for Review
Hypocapnia causes cerebral vasoconstriction and hypercapnia leads
to cerebral vasodilation. Exactly how variations in Paco2 affect
intracranial pressure and perfusion in the brains of postarrest patients,
and whether this affects outcome, remains unclear.161 This topic was
last reviewed in 2015.1,7 A SysRev144 was conducted to inform this
2020 ALS CoSTR.
Population, Intervention, Comparators, Outcomes, Study
Designs, and Time Frame
 Population: Unresponsive adults with sustained ROSC after
cardiac arrest in any setting
 Intervention: A ventilation strategy targeting a specific Paco2
 Comparators: Treatment without specific targets or with an
alternate target to the intervention
 Outcome: Critical outcomes include survival/survival with a
favourable neurological outcome at hospital discharge or 30 days;
and survival/survival with a favourable neurological outcome after
hospital discharge or 30 days (eg, 90 days, 180 days, 1 year).
 Study design: Randomized trials, non-RCTs, and observational
studies (cohort studies and case-control studies) with a control
group (ie, patients treated with no specific PaCO2 targets or an
alternative target to the intervention) were included. Animal
studies, ecological studies, case series, case reports, reviews,
abstracts, editorials, comments, and letters to the editor were not
included. There were no limitations on publication period or study
language, if there was an English abstract. The population
included patients with IHCA or OHCA of any origin. Unpublished
studies (eg, conference abstracts, trial protocols) were excluded.
The cited SysRev144 was done without age restriction, and the
evidence from adult studies (generally defined as older than 16
years or 18 years or older) is included here.
 Time frame: All years and languages were included. The literature
search was updated to August 22, 2019.
 PROSPERO Registration: CRD42020150877.
Consensus on Science
The task force concluded that differences in the PaCO2 targets used in
the arms of the 2 RCTs identified156,162 precluded meta-analysis.
For the critical outcome of favourable neurological outcome
(defined as CPC 1  2) at 6 months, we identified low-certainty
evidence from 1 RCT enrolling 120 patients and comparing a
ventilation strategy targeting high-normal PaCO2 (5.8  6.0 kPa/43.5-
45 mmHg) with one targeting low-normal PaCO2 (4.5  4.7 kPa/33.7-
35.2mmHg) and failing to showbenefit from the higher PaCO2 strategy
(RR, 0.84; 95% CI, 0.64  1.10; ARR, 113 fewer per 1000; 95% CI,
from 254 fewer to 70 more).156 For the critical outcome of favourable
neurological outcome (defined as an extended Glasgow Outcomes
Scale 5) at 6 months, we identified low-certainty evidence (down-
graded for inconsistency and imprecision) from 1 RCT enrolling
83 patients and comparing a ventilation strategy targeting moderate
hypercapnia (PaCO2 50  55mm Hg/6.7-7.3 kPa) with one targeting
normocapnia (PaCO2 35  45mm Hg/4.7-6.0 kPa) and failing to show
benefit from the higher PaCO2 strategy (RR, 1.28; 95%CI, 0.83  1.96;
ARR, 129 more per 1000; 95% CI, from 78 fewer to 443 more).162
For the critical outcome of survival to 30 days we identified low-
certainty evidence (downgraded for inconsistency and imprecision)
from 1 RCT enrolling 120 patients and comparing a ventilation
strategy targeting high-normal PaCO2 (5.8  6.0 kPa/43.5-45 mmHg)
with one targeting low-normal PaCO2 (4.5  4.7 kPa/33.7-35.2 mmHg)
and failing to show benefit from the higher PaCO2 strategy (RR, 0.81;
95%CI, 0.63  1.05;ARR, 143 fewer per 1000; 95%CI, from279 fewer
to 38 more).156
For the critical outcome of survival to discharge we identified low-
certainty evidence (downgraded for inconsistency and imprecision)
from 1 RCT enrolling 83 patients and comparing a ventilation strategy
targeting moderate hypercapnia (PaCO2 50  55mm Hg/6.7-7.3 kPa)
with one targeting normocapnia (PaCO2 35  45mm Hg/4.7-6.0 kPa)
and failing to show benefit from the higher PaCO2 strategy (RR, 1.16;
95% CI, 0.87  1.56; ARR, 101 more per 1000; 95% CI, from 82 fewer
to 355 more).162
Results were inconsistent across the 6 observational studies rated
as having less than critical risk of bias. Hypercapnia was associated
with improved outcomes in 2 studies155,163 and worse outcomes in 2
studies.149,164 There was no association between hypercapnia and
outcomes in the remaining 2 studies.152,165 Results were similar for
hypocapnia although no studies found an association with improved
outcomes.
Treatment Recommendations
There is insufficient evidence to suggest for or against targeting mild
hypercapnia compared with normocapnia in adults with ROSC after
cardiac arrest.
We suggest against routinely targeting hypocapnia in adults with
ROSC after cardiac arrest (weak recommendation, low-certainty
evidence).
Justification and Evidence-to-Decision Framework Highlights
The evidence-to-decision table is included in [1875_TD$DIFF]Supplement Appendix A-6.
Evidence from existing randomized trials and observational studies is
very inconsistent. Both randomized trials failed to show any effect from
different Paco2 targets, but the trials were small and used different target
ranges, precluding meta-analysis. Observational studies were evenly
distributed in showing benefit, harm or no effect associated with
hypercapnia. Hypocapnia results were also inconsistent, although no
studies foundanassociationwithbenefit. In lightof the lackofevidencefor
benefit, and lackof consistentevidence forharmfromPaco2 levelshigher
than normal, the task force did not think there was sufficient evidence to
suggest for or against targeting mild hypercapnia compared with
normocapnia. An ongoing trial investigating this comparison may bring
clarity to this issue (NCT03114033).
For hypocapnia, very limited evidence suggests either no benefit
or harm, supporting the task force’s suggestion against targeting
hypocapnia.
Although the task force discussed whether patients with baseline
chronic lung disease and chronic CO2 retention might respond
differently to different Paco2 targets, no evidence addressing this
subgroup was found. The task force agreed it would be reasonable to
adjust PaCO2 targets in patients with known chronic CO2 retention, but
this is expert opinion only because no evidence was identified on this
topic.
The prior treatment recommendation (2015)1,7 was a suggestion
to maintain normocapnia. The updated treatment recommendation
allows for continuing this approach, while emphasizing that we do not
currently know if targeting normocapnia is beneficial, harmful, or equal
in comparison to targeting hypercapnia. The task force discussed the
possible complication of acidemia from hypercapnia. The presence or
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absence of metabolic acidosis requires consideration when choosing
a ventilation strategy and PaCO2 target, and metabolic acidosis is
common in postarrest patients. The PaCO2 targets or ranges also
differed somewhat across studies. For this reason, the task force
chose not to define specific numeric targets because no optimal target
or range has been made clear. Additionally, opinions vary on whether
arterial blood gas analysis in patients receiving targeted temperature
management (TTM) should be adjusted for temperature. Once again,
trials differed in their approach. Approaches to blood gas interpreta-
tion in regard to temperature also varied across the observational
studies. These variations in methodology and in definitions of target
ranges prohibit the task force from being able to recommend specific
numbers or a specific method for blood gas analysis for systems
implementing these recommendations.
Knowledge Gaps
 Randomized trials comparing strategies targeting mild hypercap-
niawith strategies targeting normocapnia have thus far been small
and therefore inconclusive. A much larger randomized trial is
currently underway (NCT03114033).
 How PaCO2 targets should be adjusted in those with chronic CO2
retention is unknown.
Postresuscitation Haemodynamic Support (ALS 570: EvUp)
Population, Intervention, Comparator, and Outcome
 Population: Adults with ROSC after cardiac arrest in any setting
 Intervention: Titration of therapy to achieve a specific haemody-
namic goal (eg, mean arterial pressure greater than 65mm Hg)
 Comparator: No haemodynamic goal
 Outcome: Any clinical outcome
 An EvUp for this topic was performed and is included in [1876_TD$DIFF]
Supplement Appendix C-12. Two RCTs completed since
2015156,166 did not find that targeting a specific mean arterial
pressure affected outcome, although the studies were not
powered for clinical outcomes of survival or neurological outcome.
In the absence of ongoing RCTs, and controversy about the
targetingof higher bloodpressure, the task force suggests that this
topic be considered for a SysRev.
Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.1,7
We suggest haemodynamic goals (eg, mean arterial pressure,
systolic blood pressure) be considered during postresuscitation care
and as part of any bundle of postresuscitation interventions (weak
recommendation, low-certainty evidence).
There is insufficient evidence to recommend specific haemodynamic
goals; suchgoalsshouldbeconsideredonan individualpatientbasisand
are likely to be influenced by post-cardiac arrest status and preexisting
comorbidities (weak recommendation, low-certainty evidence).
Postresuscitation Steroids (ALS 446: EvUp)
Population, Intervention, Comparator, and Outcome
 Population: Adult patients with ROSC after cardiac arrest
(prehospital or in-hospital)
 Intervention: Treatment with corticosteroids
 Comparator: Standard care
 Outcome: Survival to hospital discharge with good neurological
outcome or survival to hospital discharge ( time to shock
reversal/shock reversal)
 The 2010 CoSTR addressed steroid use both intra-arrest and
postresuscitation.6,8 The 2015 CoSTR included only intra-arrest
steroid use.1,7 The EvUp for postresuscitation steroid use is
included in [1876_TD$DIFF]Supplement Appendix C-13. Three small RCTs and a
large observational study were identified.94,167  169 Two of the
RCTs used steroids both during CPR and after ROSC.167,168 One
recently completed trial that is not yet published was also identified
(NCT02790788). The task force recommends a SysRev be
undertaken once the recently completed trial is published.
Treatment Recommendations
This treatment (below) is unchanged from 2010.6,8
There is insufficient evidence to support or refute the use of
corticosteroids for patients with ROSC after cardiac arrest.
Prophylactic Antibiotics After Cardiac Arrest (ALS 2000:
SysRev)
Rationale for Review
This is a new topic prioritized by the ALS Task Force. Infective
complications are common in patients admitted to intensive care units
(ICUs). After cardiac arrest, pneumonia has been reported in 50% to
60%of patients,170,171 which is thought to result in part fromaspiration
during the cardiac arrest and resuscitation. In these patients, early and
accurate identification of infection is challenging. Standard criteria for
identifying infection are affected by patient treatment (ie, TTM) and the
pathophysiology of the post-cardiac arrest syndrome (ie, including the
systemic inflammatory response). The decision to treat a possible
infection needs to be balanced by the need for prudent antibiotic
administration to avoid antibiotic resistance. This new topic was
prioritized by the ALS Task Force due to the recent publication of a
SysRev on the topic.172 The published SysRev was updated by using
the ADOLOPMENT process.173
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adult patients after ROSC from cardiac arrest in any
setting (in-hospital or out-of-hospital)
 Intervention: Early/prophylactic administration of antibiotics
 Comparator: Delayed/clinically driven administration
 Outcome: Survival or survival with good neurological outcome at
hospital discharge or longer, (critical), and important outcomes of
critical care length of stay, infective complications, or duration of
mechanical ventilation
 Study design: Observational and interventional studies if they
compared the effect of administration of early or prophylactic
antibiotics with delayed or clinically driven administration of
antibiotics in adult patients after cardiac arrest. All study types that
included a control group were included. Case reports and case
series were not eligible for inclusion. There was no restriction on
language.
 Time frame: There was no restriction on publication date, and the
literature search was completed/updated in October 2019.
 PROSPERO Registration: CRD42016039358 for the original
SysRev.172
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Consensus on Science
For the critical outcome of survival with favourable neurological
outcome at ICU discharge or 30 days, we identified low-certainty
evidence (downgraded for serious risk of bias and serious impreci-
sion) from 2 RCTs171,174 enrolling 254 patients, which showed no
benefit of early/prophylactic antibiotic administration (RR, 0.89; 95%
CI, 0.71-1.12; P=0.31; risk difference,   0.06; 95% CI, 0.19-0.06;
P=0.30).
For the critical outcome of survival at ICU discharge or 30 days, we
identified low-certainty evidence (downgraded for serious risk of bias
and serious imprecision) from 2 RCTs171,174 enrolling 254 patients,
which showed no benefit (RR, 0.95; 95%CI, 0.79  1.14; P=0.60; risk
difference,   0.03; 95%CI,   0.15 to 0.08;P=0.58).We also identified
very low-certainty evidence (downgraded for serious indirectness)
from 2 observational studies. One study175 enrolling 1604 patients
showed no benefit associated with early or prophylactic antibiotic
administration compared with delayed/clinically driven administration
(OR, 1.16; 95% CI, 0.94-1.13; P=0.18). The second observational
study176 enrolling 138 patients showed a benefit (data presentation
precludes reporting of OR, P=0.01).
For the important outcome of infective complications (pneumonia)
we identified low-certainty evidence (downgraded for serious risk of
bias and serious imprecision) from 2 RCTs171,174 enrolling 254
patients, which showed no benefit (RR, 0.75; 95% CI, 0.43-1.32;
P=0.32; risk difference,   0.12; 95%CI,   0.23-0.00; P=0.05). There
were differences between the studies in methods used to diagnose
pneumonia. We found very low-certainty evidence (downgraded for
serious risk of bias, serious indirectness, and serious imprecision)
from 2 observational studies175,177 enrolling 2245 patients, which
showed no association between early/prophylactic administration
compared with delayed/clinically driven administration (OR, 0.61;
95% CI, 0.61-1.62; P=0.98). These studies, too, differed in methods
used to diagnose pneumonia.
For the important outcome of critical care length of stay we
identified low-certainty evidence (downgraded for serious risk of bias
and serious imprecision) from 2 RCTs171,174 enrolling 248 patients,
which showed no benefit (mean difference, 0.47 days; 95%CI,   1.31-
2.24; P=0.61).
For the important outcomeof duration ofmechanical ventilationwe
identified very low-certainty evidence (downgraded for very serious
risk of bias and serious imprecision) from 1 RCT174 enrolling
60 patients, which showed no benefit (mean difference, 0.20 days;
95% CI,   1.53-1.93; P=0.82).
Treatment Recommendation
Wesuggest against the use of prophylactic antibiotics in patients after
ROSC (weak recommendation, low-certainty evidence).
Justification and Evidence-to-Decision Framework Highlights
The evidence-to-decision table is included in [1875_TD$DIFF]Appendix ASupplement
Appendix A-7. Meta-analyses of both randomized trials and
observational studies showed no overall benefit in the use of
prophylactic antibiotics during post-cardiac arrest care. The task
force did review the findings of 1 RCT at low overall risk of bias that
reported reduced incidence of early pneumonia in patients treated
with prophylactic antibiotics.171 Although this study demonstrated the
potential efficacy of prophylactic antibiotics, there was no improve-
ment in other clinical outcomes, such as survival or critical care length
of stay. Pneumonia affects approximately 50% of ICU patients after
cardiac arrest, but this is unlikely to contribute to mortality because
most deaths are attributable to neurological failure, cardiovascular
failure, ormultiorgan failure.170,171 A strategy of prophylactic antibiotic
use would likely expose a large number of patients to antibiotics with
no specific benefit and increase the risk of development of resistant
organisms. The decision to administer antibiotics after cardiac arrest,
particularly in the context of gastric aspiration, is challenging and
clinicians may have different clinical thresholds for prescribing
antibiotics.We did not identify anyRCTs enrolling patients after IHCA.
Knowledge Gaps
 Studies of post-ROSC antibiotics after IHCA.
 RCTs that evaluate this question in patients treated with TTM at
temperatures other than 32 C to 34 C.
 RCTs powered to determine the effect of prophylactic antibiotics
on outcomes such as critical care length of stay or duration of
mechanical ventilation.
Post-Cardiac Arrest Seizure Prophylaxis and Treatment (ALS
431, 868: SysRev)
Rationale for Review
Hypoxic-ischemic brain injury is a common cause of death in
comatose cardiac arrest survivors. Clinical convulsions and epilepti-
form activity in the electroencephalogram (EEG) are common, with
substantial overlap and an approximate incidence of 20% to 30%.178
  181 The prognosis for patients with clinical and electrographic
seizures is usually poor, but somepatients recover andmay ultimately
have a good neurological outcome.180,181 This CoSTR is based on an
update of the 2015 SysRev and CoSTR1,7 for seizure prophylaxis and
treatment in cardiac arrest survivors.
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Unresponsive adults (older than 18 years) with
sustained ROSC after cardiac arrest in any setting (in-hospital or
out-of-hospital)
 Intervention: One strategy for seizure prophylaxis or treatment
 Comparator: Another strategy or no seizure prophylaxis or
treatment
 Outcome: Survival with favourable neurological/functional out-
come at discharge, 30 days, 60 days, 180 days, and/or 1 year;
survival at discharge, 30 days, 60 days, 180 days, and/or 1 year
(all critical); and the important outcomeof seizure incidence during
index hospitalization (for seizure prophylaxis only)
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) are eligible for inclusion. Unpublished studies (eg,
conference abstracts, trial protocols) are excluded.
 Time frame: All years and languageswere included if therewas an
English abstract; unpublished studies (eg, conference abstracts,
trial protocols) were excluded. The literature search was updated
to September 26, 2019.
 PROSPERO Registration: Registered with ILCOR Science
Advisory Committee October 3, 2019. This SysRev was done
as an update of the 2015 CoSTR SysRev and PROSPERO
registration was not done.
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Consensus on Science
Post-Cardiac Arrest Seizure Prophylaxis. For the critical outcomes
of survival with favourable neurological outcome to discharge/30 days
or longer, and survival to discharge/30 days or longer, 2 prospective
RCTs involving a total of 562 subjects provided very low-certainty
evidence (downgraded for risk of bias, indirectness and imprecision)
182,183 of no benefit from seizure prophylaxis. One nonrandomized
prospective clinical trial with 107 subjects that used historic controls
provided very low-certainty evidence (downgraded for risk of bias,
indirectness, and imprecision) of no benefit.184
For the important outcomeof seizure prevention,we identified very
low-certainty evidence (downgraded for risk of bias and indirectness
and imprecision) from 2 prospective double-blinded RCTs182,183
showing no benefit of seizure prophylaxis.
Post-Cardiac Arrest Seizure Treatment. For the critical outcomes of
survivalwith favourableneurological outcomeor survival at discharge/
30 days or longer, we identified no RCTs or nonrandomized studies
that addressed the effect of post-cardiac arrest seizure treatment,
compared with no seizure treatment, on outcomes.
Treatment Recommendations
This treatment recommendation has been updated from 2015.1,7
We suggest against seizure prophylaxis in adult post-cardiac
arrest survivors (weak recommendation, very low-certainty evidence).
We suggest treatment of seizures in adult post-cardiac arrest
survivors (weak recommendation, very low-certainty evidence).
Justification and Evidence-to-Decision Framework Highlights
The evidence-to-decision table is included in [1875_TD$DIFF]Supplement
Appendix A-8. The task force decision to suggest against post-
cardiac arrest seizure prophylaxis was primarily based on the
absence of direct evidence that prophylactic therapy with antiepi-
leptic drugs prevents seizures or improves important outcomes in
adult comatose cardiac arrest survivors. However, the task force did
recognize the very low certainty of the evidence from RCTs. The
task force also considered that seizure prophylaxis in other forms of
acute brain injury is not associated with improved outcomes, and
that most drugs used for seizure prophylaxis can have significant
side effects. Finally, the task force acknowledged that most
comatose cardiac arrest survivors routinely receive sedatives such
as propofol or benzodiazepines that are known to have antiepileptic
effects. However, the task force identified no controlled studies that
examined whether different sedation strategies or choices of
sedation drugs had an impact on the incidence of post-cardiac
arrest seizures.
The task force decision to suggest treatment of seizures in post-
cardiac arrest survivors takes into consideration the absence
of direct evidence that seizure treatment improves critical outcomes
in this patient population. However, there are no published
controlled clinical studies. Therefore, the task force weighed
the fact that ongoing seizures have the potential to worsen brain
injury, and treatment of recurrent seizures and status epilepticus
constitutes “standard of care” in other patient populations. A
large randomized trial is currently underway investigating
the benefit of systematic antiepileptic drug therapy with the goal
of suppressing all epileptiform activity on the EEG versus
standard treatment of clinical seizures only in post-cardiac arrest
status epilepticus. (TELSTAR trial [Treatment of Electroencepha-
lographic Status Epilepticus After Cardiopulmonary Resuscitation],
NCT02056236)
Indirect evidence fromcaseseries suggests that sedatives suchas
propofol are effective in suppressing both clinical convulsions and
epileptiform activity on EEG in these patients.185  187 A recent
retrospective study provides some evidence that conventional
antiepileptic drugs (specifically valproate and levetiracetam) also
have an effect in suppressing epileptiform activity in the EEG.188 In a
recent comparison of valproate, levetiracetam, and fosphenytoin for
convulsive status epilepticus, the 3 drugs were equally effective but
fosphenytoin caused more episodes of hypotension and need for
tracheal intubation.189 However, it is important to note that this study
excluded post-cardiac arrest patients. On the basis of these results,
the task forcediscussedusing valproate and levetiracetamas first-line
drugs in post-cardiac arrest seizure treatment.
There is no direct evidence of undesirable effects of antiepileptic
drug therapy in comatose post-cardiac arrest survivors. Treatment
with sedatives and conventional antiepileptic drugs in high doses has
the potential to cause delayed awakening, prolonged need for
mechanical ventilation, and increased critical care days. Importantly,
generalized myoclonus in combination with epileptiform discharges
may be manifestations of Lance-Adams syndrome, which is
compatible with a good outcome.187,190 In such cases, overly
aggressive sedation and treatment with high doses of conventional
antiepileptic drugs may confound the clinical examination and lead to
overly pessimistic prognostication.
The relative benefit of continuous EEG compared with intermittent
EEG monitoring was not specifically reviewed. Continuous EEG
monitoring is labor intensive and likely to add significant cost to patient
care. The net cost-effectiveness of this approach is controversial and
may depend substantially on the setting.191,192 The task force also
discussed the potential cost of delayed neurological prognostication
and prolonged ICU care associated with active treatment of seizures
because of the need to continue sedation.
Knowledge Gaps
 There is no high-certainty evidence of a positive effect of
antiepileptic drugs on the outcome of post-cardiac arrest patients
with seizures.
 There are no RCTs specifically designed to evaluate the impact of
post-cardiac arrest seizure prophylaxis on the incidence of
seizures and on neurological outcome.
 There are inadequate data about the timing, duration, dosing, and
choice of antiepileptic drugs for seizure prophylaxis in comatose
post-cardiac arrest patients.
 The utility of continuous EEG versus intermittent EEG monitoring
in the diagnosis and treatment of seizures in comatose post-
cardiac arrest patients remains controversial.
 The threshold for treating epileptiform activity other than
convulsive seizures (eg, generalized epileptiform discharges) is
poorly defined.
 Standardized terminology for classification of epileptiform activity
in theEEGof comatosepost-cardiac arrest patients is increasingly
used. There remains a need to develop consensus on the
definition of post-cardiac arrest status epilepticus.
 The value of using volatile anesthetics to treat refractory status
epilepticus on post-cardiac arrest patients is currently unknown.
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Targeted Temperature Management (ALS 455, 790, 791, 802,
879: EvUp)
A comprehensive SysRev of TTM193,194 was conducted for the 2015
CoSTR.1,7 The task force chose to delay updating this SysRev until the
completion and publication of theTargetedHypothermiaVersus Targeted
Normothermia After Out-of-Hospital Cardiac Arrest (TTM2) RCT
(NCT02908308).EvUps foruseofTTMandTTMdurationwerecompleted
and appear in [1876_TD$DIFF]Supplement Appendix C-14 and C-15.
The results of theHYPERION trial (Therapeutic HypothermiaAfter
Cardiac Arrest in Nonshockable Rhythm) were recently published.195
In this French trial, 581 adult patients who were comatose after
resuscitation from either an IHCA or OHCA with an initial non-
shockable rhythm were randomized to either TTM with a target
temperature of 33 C or TTM with a temperature of 37 C, both for
24 hours. The primary outcome (the proportion of patients with a CPC
of either 1 or 2 at 90 days after the cardiac arrest) significantly favored
the 33 C group. At 90 days, 29 of 284 patients (10.2%) in the 33 C
group were alive with a CPC of 1 or 2, as compared with 17 of 297
(5.7%) in the normothermia group (risk difference, 4.5%; 95% CI, 0.1
  8.9;P=0.04). Therewasnodifference inmortality at 90 days (81.3%
versus 83.2%; risk difference,   1.9%; 95% CI,   8.0 to 4.3).
This trial does not lead to any immediate changes to the 2015
ILCOR treatment recommendations1,7 but reinforces the suggestion
to consider TTM, targeting a constant temperature between 32C and
36C, in patients who remain comatose after resuscitation from either
IHCA or OHCA with an initial nonshockable rhythm.
Treatment Recommendations
These treatment recommendations are unchanged from 2015.1,7
We recommend selecting and maintaining a constant target
temperature between 32 C and 36 C for those patients in whom
temperaturecontrol isused (strong recommendation,moderate-quality
evidence). Whether certain subpopulations of cardiac arrest patients
may benefit from lower (32 C   34 C) or higher (36 C) temperatures
remains unknown, and further research may help elucidate this.
We recommend TTM as opposed to no TTM for adults with OHCA
with an initial shockable rhythmwho remain unresponsive after ROSC
(strong recommendation, low-quality evidence).
We suggest TTM as opposed to no TTM for adults with OHCAwith
an initial nonshockable rhythm who remain unresponsive after ROSC
(weak recommendation, very low-quality evidence).
We suggest TTM as opposed to no TTM for adults with IHCA with
any initial rhythm who remain unresponsive after ROSC (weak
recommendation, very low-quality evidence).
We suggest that if TTM is used, duration should be at least
24 hours (weak recommendation, very low-quality evidence).
We recommend against routine use of prehospital cooling with
rapid infusion of large volumes of cold IV fluid immediately after ROSC
(strong recommendation, moderate-quality evidence).
We suggest prevention and treatment of fever in persistently
comatose adults after completion of TTM between 32 C and 36 C
(weak recommendation, very low-quality evidence).
Prognostication in Comatose Patients After Resuscitation
From Cardiac Arrest
Combined Prognostic Systematic Reviews
Many comatose post-cardiac arrest patients will not survive or will
survive with an unfavourable neurological outcome. In some regions,
family and treating teams may limit or withdraw life-sustaining
treatment when unfavourable neurological outcomes are expected.
Therefore, reliable strategies for timely prognostication are a critical
component of any cardiac arrest system of care. The 2015 CoSTR
distinguished between studies of prognostication among patients
treated with or without hypothermia. For this 2020 CoSTR for ALS,
these treatment recommendations apply regardless of the TTM
strategy used. The reason for this is that in all of the studies we
assessed, the population included a mix of TTM-treated and non
  TTM-treated patients, and the potential impact of TTM on
prognostication could not be assessed separately.
On May 31, 2013, a new search was launched, using the search
strategies used for previous SysRevs on neuroprognostication. For
the SysRev informing the 2020 CoSTRs, the search included studies
published from January 1, 2013, to December 31, 2019 [PROSPERO
Registration: CRD42019141169].
This review identified clinical signs, neurophysiological measure-
ments, bloodbiomarkers, and imaging studies that hadhigh specificity
for poor neurological outcome, defined as CPC score of 3 to 5 or mRS
score of 4 to 6 at hospital discharge, 1 month, or later.
The decision to limit treatment of comatose post-cardiac arrest
patients should never rely on a single prognostication element. The
consensus of the task forcewas that in patients who remain comatose
in the absence of confounders (eg, sedative drugs), a multimodal
approach should be used, with all supplementary tests considered in
the context of the clinical examination. The most reliable combination
and timing for each assessment are still to be determined and require
further research.
The SysRevs supporting this CoSTR defined prediction as
imprecise when the upper limit of 95% CIs for false-positive rate
was above 5%.196 However, there is no universal consensus on what
the acceptable limits for imprecision should be. In a recent survey of
640 medical providers, Steinberg et al197 reported that 56%
considered an acceptable false-positive rate for withdrawal of life
sustaining treatment from patients who might otherwise have
recovered was 0.1% or less. In addition, 59% of respondents felt
that an acceptable false-positive rate threshold for continuing life-
sustaining treatment in patients with unrecognized unrecoverable
injury was 1% or less.
Clinical Examination for Prognostication (ALS 450, 713, 487:
SysRev)
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults who are comatose after resuscitation from
cardiac arrest (either in-hospital or out-of-hospital), regardless of
target temperature
 Intervention: Pupillary light reflex (PLR), pupillometry, corneal
reflex, myoclonus, and status myoclonus assessed within 1 week
after cardiac arrest
 Comparator: None
 Outcome: Prediction of poor neurological outcome defined as
CPC 3 to 5 or mRS 4 to 6 at hospital discharge, 1 month, or later
 Study design: Prognostic accuracy studies where the
22 contingency table (ie, the number of true/false negatives
and positives for prediction of poor outcome) was reported, or
where those variables could be calculated from reported data, are
eligible for inclusion. Unpublished studies, reviews, case reports,
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case series, studies including fewer than 10 patients, letters,
editorials, conference abstracts, and studies published in abstract
form were excluded.
 Time frame: In 2015, an ILCOR evidence review identified
4 categories of predictors of neurological outcome after cardiac
arrest, namely clinical examination, biomarkers, electrophysiolo-
gy, and imaging. In the last 4 years, several studies have been
published and new predictors have been identified, therefore the
topic needs an update.
 The most recent search of the previous SysRevs on neuro-
prognostication was launched on May 31, 2013. We searched
studies published from January 1, 2013, to December 31, 2019.
 PROSPERO Registration: CRD42019141169
Consensus on Science
Pupillary Reflex. Theassociation of a bilaterally absent standardPLR,
measured at various time points, with outcome was investigated in 17
observational studies.198  214 Althoughall of this evidencewas rated as
very lowcertainty, studies that evaluated theprognostic valueof absent
standardPLRat timepointsof72 hoursormoreafterROSChadgreater
specificity (ranging from 90% to 100%) for unfavourable neurological
outcome at time points from discharge to 12 months than studies that
used the absence of PLRat less than 72hours (specificity ranging from
48% to 92%). Sensitivity appeared to decreasewhenusing a timepoint
of 72 hours or more, but specificity was identified as the higher priority
given the critical importance of avoiding false positives.
Pupillometry. Automated assessment of PLR can be made by
measuring either of the following variables:
 The percent reduction in pupillary size, which is reported as qPLR,
or
 The neurological pupil index (NPi), which is based on several
variables such as pupillary size, percentage of constriction,
constriction velocity, and latency.
Automated Pupillometry Using Percent of Pupillary Size
Reduction (qPLR). In 3 observational studies using various time
points,209,215,216 qPLR from 0% to 13% at 24 hours predicted poor
neurological outcome from 3 months to 12 months with specificity
ranging from 77.8% to 98.9% and sensitivity from 17% to 66%
(certainty of evidence frommoderate to very low). When evaluated at
48 hours, specificity ranged from 95.7% to 100% and sensitivity from
18.1% to 58.5% (certainty of evidence from low to very low). In 1 study
of 234 patients209 qPLR=0% at 72 hours predicted poor neurological
outcome at 3 months with 100% specificity and 4.9% sensitivity
(moderate certainty of evidence).
Automated Pupillometry Using Multiple Variables (NPi). In 3
observational studies,209,217,218 NPi from 0 to 2.40 within 24 hours
predicted poor neurological outcome from hospital discharge to
3 months with 100% specificity and sensitivity ranging from 22% to
43.9% (certainty of evidence frommoderate to very low). For the same
outcome, 1 study with 361 patients209 found that NPi 2 or less at
48 hours had 100%specificity and 18.8% sensitivity, andNPi 2 or less
at 72 hours had 100% specificity, and 16.9% sensitivity (moderate
certainty of evidence).
Corneal Reflex. Corneal reflex at various time points was
investigated in 11 observational studies.198,200,202,204
  206,210,211,213,214,219 Although all of the evidence was rated as very
low certainty, studies that evaluated the prognostic value of absent
corneal reflex at time points of 72 hours or more after ROSC had
greater specificity (ranging from 89% to 100%) for unfavourable
neurological outcome from hospital discharge to 12 months after
ROSC thanstudies that used theabsenceof corneal reflexat less than
72 hours (specificity ranging from 25% to 89%). Sensitivity appeared
to decreasewhenusinga timepoint of 72 hours ormore, but specificity
was determined to be a higher priority given the critical importance of
avoiding false positives.
Myoclonus. Presence of myoclonus within 96 hours after ROSC was
investigated in 6 studies200,210,219  222 and predicted poor neurologi-
cal outcome from hospital discharge to 6 months with specificity
ranging from 77.8% to 100% and sensitivity ranging from 18.2% to
44.4% (very low-certainty evidence). However, definitions of myoclo-
nus were provided in only 1 study.220
Status Myoclonus. Presence of status myoclonus within 72hours
after ROSC was investigated in 2 studies178,223 and predicted poor
neurological outcome from hospital discharge to 6 months with
specificity ranging from 99.8% to 100% and sensitivity ranging from
12.2% to 49.1% (very low-certainty evidence). The definitions of
status myoclonus differed between these 2 studies.
Treatment Recommendations
We recommend that neuroprognostication always be undertaken by
using a multimodal approach because no single test has sufficient
specificity to eliminate false positives (strong recommendation, very
low-certainty evidence).
We suggest using PLR at 72hours or more after ROSC for
predicting neurological outcome of adults who are comatose after
cardiac arrest (weak recommendation, very low-certainty evidence).
We suggest using quantitative pupillometry at 72 hours or more
after ROSC for predicting neurological outcome of adults who are
comatose after cardiac arrest (weak recommendation, low-certainty
evidence).
We suggest using bilateral absence of corneal reflex at 72 hours or
more after ROSC for predicting poor neurological outcome in adults
who are comatose after cardiac arrest (weak recommendation, very
low-certainty evidence).
We suggest using presence of myoclonus or status myoclonus
within 7 days after ROSC, in combination with other tests, for
predictingpoor neurological outcome inadultswhoare comatoseafter
cardiac arrest (weak recommendation, very low-certainty evidence).
We also suggest recording EEG in the presence of myoclonic jerks to
detect any associated epileptiform activity (weak recommendation,
very low-certainty evidence).
Justification and Evidence-to-Decision Framework Highlights
As noted in the previous CoSTR on this topic in 2015,1,7 the task force
consensus is that a multimodal approach should be used in all cases
with all supplementary tests considered in the context of the clinical
examination.
The evidence-to-decision tables are included in [1875_TD$DIFF]Supplement
Appendixes A-9, 10, 11, and 12. For standard PLR, NPi, and corneal
reflex, the suggestion to use these findings at 72 hours or more after
ROSCwas based both on the specificity found in different studies and
on the perceived importance of eliminating confounding effects of
sedatives or muscle relaxants as much as possible. Only some of the
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included studies specifically excluded the presence of residual
sedation at the time the pupillary or corneal reflex was assessed.
For assessment of the pupillary reflex, the task force felt that NPi
has the potential for being more accurate and less prone to bias and
subjectivity. This benefit, however, may be counterbalanced by the
need for more equipment and specialized training to obtain the NPi.
Resultsofclinicalexaminationusuallycannotbeconcealed fromthe
treating team. Therefore, a risk of self-fulfilling prophecy exists even
when index tests thatarebasedonclinical examinationarenotexplicitly
included in the criteria for withdrawal of life-sustaining therapy.
Although definitions of both myoclonus and status myoclonus are
missing frommost studies andare inconsistent in others, thepresence
of myoclonus is associated with poor outcome in patients who are
comatose after ROSC from cardiac arrest and the finding may be
useful within the context of a multimodal prognostic assessment.
Myoclonus and status myoclonus are inconsistently associated with
epileptiform activity on the EEG. Importantly, generalized myoclonus
associated with favourable clinical features, such as a continuous or
reactive EEG background or preserved brain stem reflexes, may be
manifestations of Lance-Adams syndrome, which is compatible with a
good outcome.187,190
Knowledge Gaps
 Absence of residual effects from sedatives must be specifically
assessed in studies evaluating the accuracy of predictors on the
basis of clinical examination after cardiac arrest.
 The interrater agreement for the assessment of standard PLR,
corneal reflex, and myoclonus/status myoclonus in patients
resuscitated from cardiac arrest deserves investigation.
 The number of studies documenting pupillometry for predicting
poor outcomeafter cardiac arrest is still low.Aconsistent threshold
for 100% specificity has not been identified for qPLR or NPi.
 Achieving a uniform and consensus-based definition of both
myoclonusandstatusmyoclonus is necessary. The role ofEEGas
an additional tool to investigate the nature and the prognostic
significance of myoclonus deserves investigation.
 The most reliable combination and timing for each assessment
remains to be determined.
 The potential impact of TTM on prognostication remains to be
determined.
Neurophysiological Tests for Prognostication (ALS 450, 713,
460: SysRev)
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults who are comatose after resuscitation from
cardiac arrest in any setting (in-hospital or out-of-hospital) and
regardless of target temperature
 Intervention: Electrophysiology studies assessed within 1 week
after cardiac arrest
 Comparator: None
 Outcome: Prediction of unfavourable neurological outcome
defined as CPC 3 to 5 or mRS 4 to 6 at hospital discharge, 1
month, or later
 Study design: Prognostic accuracy studies where the
2 2 contingency table (ie, the number of true/false negatives
and positives for prediction of poor outcome) was reported, or
where those variables could be calculated from reported data, are
eligible for inclusion. Unpublished studies, reviews, case reports,
case series, studies including fewer than 10 patients, letters,
editorials, conference abstracts, and studies published in abstract
form are excluded.
 Time frame: In 2015,1,7 an ILCOR evidence review identified
4 categories of predictors of neurological outcome after cardiac
arrest, namely clinical examination, biomarkers, electrophysiolo-
gy, and imaging. In the last 4 years, several studies have been
published and new predictors have been identified, therefore the
topic needs an update.
 The most recent search of the previous SysRevs on neuro-
prognostication was launched on May 31, 2013. We searched
studies published from January 1, 2013, to December 31, 2019.
 PROSPERO Registration: CRD42019141169
Consensus on Science
Somatosensory Evoked Potentials. The prognostic value of
somatosensory evoked potentials (SSEPs) was investigated in 14
observational studies.199,205,208  211,214,224  230 In 4 stud-
ies,205,224,228,229 bilaterally absent N20 SSEP wave within 24 hours
after ROSC predicted poor neurological outcome from hospital
discharge to 6 months. Specificity was 100% and sensitivity ranged
from 33.3% to 57.7% (very low-certainty evidence). In 1 study,199 an
absent N20 wave on one side and an absent or low-voltage N20wave
on the other side within 24 hours after ROSC predicted poor
neurological outcome at 6 months. Specificity was 100% and
sensitivity was 49.6% (very low-certainty evidence).
In 12 studies,205,208  211,214,225  230 bilaterally absent N20 SSEP
wave at 24 to 96 hours after ROSC predicted poor neurological
outcome from hospital discharge to 6months. Specificity ranged from
50% to 100% and sensitivity ranged from 18.2% to 69.1% (very low-
certainty evidence).
Unreactive EEG. The prognostic value of an unreactive EEG was
investigated in 10observational studies.210,219,229,231  237 In 9of these
studies,210,219,229,232  237 an unreactive EEG within 72 hours after
ROSC predicted poor neurological outcome from hospital discharge
to 6 months. Specificity ranged from 41.7% to 100% and sensitivity
ranged from 50% to 97.1% (certainty of evidence from moderate to
very low). Specificity was below 90% in most of these studies,
reaching 100% in only 2 of them.
In 1 study,231 an unreactive EEG at a median of 77 hours after
ROSC (interquartile range [IQR], 53  102) predicted poor neurologi-
cal outcome at 6 months with 70% specificity and 88.1% sensitivity
(very low-certainty evidence).
Rhythmic/Periodic Discharges. The prognostic value of rhythmic/
periodic discharges were investigated in 9 observational stud-
ies.199,210,228,231,237  241
In 2 studies,199,238 rhythmic/periodic discharges within 24 hours
after ROSC predicted poor neurological outcome from 3 months to
6 months. Specificity was 100% and sensitivity ranged from 2.4% to
7.9% (certainty of evidence from moderate to very low).
In 4 studies,210,228,238,239 rhythmic/periodic discharges within
48 hours after ROSC predicted poor neurological outcome from
3 months to 6 months. Specificity ranged from 97.2% to 100% and
sensitivity ranged from 8.1% to 42.9% (certainty of evidence from
moderate to very low).
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In 3 studies,228,237,239 rhythmic/periodic discharges at 48 to
72hours after ROSC predicted poor neurological outcome from
1 month to 6 months. Specificity ranged from 66.7% to 96.1% and
sensitivity ranged from11.4% to 50.8% (certainty of evidence from low
to very low).
In 2 studies,231,240 rhythmic/periodic discharges at the median
time of 76 to 77 hours after ROSC predicted poor neurological
outcome at 6 months. Specificity ranged from 97% to 100% and
sensitivity ranged from 5% to 40% (certainty of evidence from low to
very low).
In 1 study,241 rhythmic/periodic discharges within 5 days after
ROSC predicted poor neurological outcome at 6 months. Specificity
was 100% and sensitivity was 15.7% (moderate certainty of
evidence).
Sporadic, Nonrhythmic/Periodic Discharges. The prognostic value
of sporadic, nonrhythmic/periodic discharges was investigated in 5
observational studies.199,226,228,237,238 In 3 studies,199,226,238 sporad-
ic, nonrhythmic/periodic discharges within 24 hours after ROSC
predicted poor neurological outcome from 3 months to 6 months.
Specificity ranged from 84.6% to 100% and sensitivity ranged from
0.5% to 7.9% (certainty of evidence from moderate to very low).
In 3 studies,226,228,238 sporadic, nonrhythmic/periodic discharges
within 48 hours predicted poor neurological outcome from 3months to
6 months. Specificity ranged from 95.8% to 99.5% and sensitivity
ranged from 0.4% to 13.3% (certainty of evidence from moderate to
very low).
In 3 studies,226,228,237 sporadic, nonrhythmic/periodic discharges
at 48 to 72hours predicted poor neurological outcome from1month to
6 months. Specificity ranged from 88.9% to 97.3% and sensitivity
ranging from 0.6% to 38.5% (certainty of evidence from low to very
low).
In 1 study,226 sporadic, nonrhythmic/periodic discharges at 96 to
120 hours predicted poor neurological outcome at 6 months.
Specificity ranged from 66.7% to 82.1% and sensitivity ranged from
17.6% to 21.3% (very low-certainty evidence).
Seizures. The prognostic implications of seizures were investigated
in 5 observational studies.220,231,236  238 In 4 of these studies, seizures
were recorded within 72hours after ROSC, and in 1 study,231 they
were recorded at amedian of 77 (53  102) hours after ROSC. In these
studies, the presence of seizures predicted poor neurological
outcome from hospital discharge to 6 months with 100% specificity
and sensitivity ranging from0.6% to 26.8% (certainty of evidence from
moderate to very low).
The prognostic implications of status epilepticuswere investigated
in 6 studies.202,225,236,241  243 The definitions of status epilepticus
were inconsistent across studies. In these studies, status epilepticus
within 5 days after ROSC predicted poor neurological outcome from
hospital discharge to 6 months. Specificity ranged from 82.6% to
100% and sensitivity ranged from 1.8% to 50% (certainty of evidence
low to very low).
In 3 of these studies,202,225,236 EEG was recorded within 72 hours
after ROSC and specificity was 100%. In another study,243 specificity
was 100% only when status epilepticus originated from a discontinu-
ous or burst-suppression background.
Burst Suppression. The possible prognostic value of burst suppres-
sion was investigated in 6 observational studies.202,220,225,231,233,240
In 2 studies,220,233 burst suppression within 24 hours after ROSC
predicted poor neurological outcome tohospital dischargewith 50% to
100% specificity and 50% to 51.5% sensitivity (certainty of evidence
very low).
In 5 studies,202,225,231,233,240 burst suppression at 24 to 120 hours
after ROSC predicted poor neurological outcome at hospital
discharge to 6 months. Specificity ranged from 91.7% to 100% and
sensitivity ranged from13.9% to 55.6% (certainty of evidence from low
to very low).
Definitions of burst suppression used in these studies varied
when they were included at all. In 2 studies,231,240 the American
Clinical Neurophysiology Society definition244 was used. In 1 study,
a non-American Clinical Neurophysiology Society definition was
used, while in the remaining studies, no specific definition was
used.
Synchronous Burst Suppression. In 1 study,226 a synchronous
burst suppression at 6 to 96hours after ROSC predicted poor
neurological outcomeat 6monthswith 100%specificity and sensitivity
ranging from 1.1% to 31.7% (certainty of evidence from moderate to
low).
Heterogeneous Burst Suppression. In 1 study,226 heteroge-
neous burst suppression at 6 to 120 hours after ROSC predicted poor
neurological outcome at 6 months. Specificity ranged from 90.7% to
100% and sensitivity ranged from 1.1% to 16.2% (certainty of
evidence from moderate to very low).
Treatment Recommendations
We recommend that neuroprognostication always be undertaken by
using a multimodal approach because no single test has sufficient
specificity to eliminate false positives (strong recommendation, very
low-certainty evidence).
We suggest using a bilaterally absent N20 wave of SSEP in
combination with other indices to predict poor outcome in adult
patients who are comatose after cardiac arrest (weak recommenda-
tion, very low-certainty evidence).
We suggest against using the absence of EEG background
reactivity alone to predict poor outcome in adult patients who are
comatose after cardiac arrest (weak recommendation, very low-
certainty evidence).
We suggest using the presence of seizure activity on EEG in
combination with other indices to predict poor outcome in adult
patients who are comatose after cardiac arrest (weak recommenda-
tion, very low-certainty evidence).
We suggest using burst suppression on EEG in combination with
other indices to predict poor outcome in adult patients who are
comatose and effects of sedation after cardiac arrest have cleared
(weak recommendation, very low-certainty evidence).
Justification and Evidence-to-Decision Framework Highlights
The evidence-to-decision tables are included in [1875_TD$DIFF]Supplement Appen-
dixes A-13, 14, 15, 16, and 17.
In making a recommendation about use of SSEPs for prognosti-
cation, the task force considered that SSEPs have a low risk of
confounding from TTM or sedation and a large size of effect (high
precision). However, to limit the risk of self-fulfilling prophecy,
combining evaluation of SSEPswith other indices of poor neurological
outcome is prudent.
In almost all studies, we reported the specificity of unreactive EEG
background for predicting poor outcome, and its precision was low. In
addition, both definitions of stimuli to induce EEG reactivity were
inconsistent across studies.
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In most of the studies, we included the specificity of rhythmic/
periodic epileptiform activity for predicting poor outcome as 100%.
Specificity was lower for sporadic epileptiform discharges.
In all studies, we included the specificity of American Clinical
NeurophysiologySociety-defined seizures onEEG for predicting poor
outcome as 100%.244 This specificity was consistent throughout the
first 72 hours after ROSC.
Specificity of status epilepticus for predicting poor outcome was
100% in only half of the studies we included. An additional challenge
for use of studies of status epilepticus for prognostication is the
inconsistency of its definitions in reported studies.
In all studies we included, the presence of burst suppression on
EEG predicted poor neurological outcome with a specificity above
90%, and inmost studies, the specificity was 100%.Because sedative
agents can affect the EEG, the most prudent strategy is to assess
burst suppression for prognostication when any effects of sedation
medications have cleared.
Knowledge Gaps
 Further studies are needed to evaluate the added value of
assessing SSEPs in combination with other predictors of poor
neurological outcome after cardiac arrest.
 It is desirable that future studies adopt a standard definition of
backgroundEEG reactivity. An international consensus statement
on EEG reactivity testing (eg, stimulus protocol) has been
proposed.245
 It is desirable that future studies adopt a standard definition of
epileptiform discharges.
 The specific predictive value of the different epileptiform subtypes,
their prevalence, and their combination with background EEG
deserves further investigation.
 Precision was low or very low in most studies of the association of
seizures with outcome. Further studies are needed to confirm the
predictive value of seizures for poor outcome after cardiac arrest.
 A standard definition of status epilepticus is urgently needed.
 It is desirable that future studies adopt a standard definition of
burst suppression, such as the one included in the American
Clinical Neurophysiology Society’s Standardized Critical Care
EEG Terminology.244
 Theaccuracyof synchronousburst suppression forprognostication
(identical/highly epileptiform bursts) deserves further investigation.
 It is desirable to achieve a consensus definition of the term, “highly
malignant EEG patterns” in patients who are comatose after
resuscitation from cardiac arrest.
 The potential impact of TTM on prognostication remains to be
determined.
Blood Biomarkers for Prognostication (ALS 450, 713, 484:
SysRev)
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults who are comatose after resuscitation from
cardiac arrest in any setting (in-hospital or out-of-hospital) and
regardless of target temperature
 Intervention: The use of neuron-specific enolase (NSE), S-100B,
glial fibrillary acidic protein, serum tau protein, and neurofilament
light chain assessed within 1 week after cardiac arrest
 Comparator: None
 Outcome: Prediction of unfavourable neurological outcome,
defined as CPC 3 to 5 or mRS 4 to 6 at hospital discharge, 1
month, or later
 Study design: Prognostic accuracy studies where the
22 contingency table (ie, the number of true/false negatives
and positives for prediction of poor outcome) was reported, or
where those variables could be calculated from reported data, are
eligible for inclusion. Unpublished studies, reviews, case reports,
case series, studies including fewer than 10 patients, letters,
editorials, conference abstracts, and studies published in abstract
form were excluded.
 Time frame: In 2015, an ILCOR evidence review1,7 identified
4 categories of predictors of neurological outcome after cardiac
arrest, namely clinical examination, biomarkers, electrophysiolo-
gy, and imaging. In the last 4 years, several studies have been
published and new predictors have been identified, therefore the
topic needs an update.
 The most recent search of the previous SysRevs on neuro-
prognostication was launched on May 31, 2013. We searched
studies published from January 1, 2013, to December 31, 2019.
 PROSPERO Registration: CRD42019141169
Consensus on Science
Neuron-Specific Enolase. The prognostic value of NSE was
investigated in 12 observational studies.202,206,208,214,239,246  252 In
these studies, NSEwith thresholds ranging from 33 to 120mg/L within
72 hours after ROSC predicted poor neurological outcome from
hospital discharge to 6 months. Specificity ranged from 75% to 100%
and sensitivity ranged from 7.8% to 83.6% (certainty of evidence from
moderate to very low).
In 1 study,248 NSE with a threshold of 50.2mg/L at day 4 (after
ROSC) predicted poor neurological outcome at 1 month with 100%
specificity and 42.1% sensitivity (moderate certainty of evidence).
S-100B. The accuracy of S-100B protein in predicting poor outcome
in patients with ROSC after cardiac arrest was investigated in 3
observational studies.251,253,254
In 2 studies,251,254S-100Bproteinwith threshold ranging from3.58
to 16.6mg/L immediately after ROSC predicted poor neurological
outcome from 3 to 6 months with 100% specificity and sensitivity
ranging from 2.8% to 26.9% (certainty of evidence from moderate to
very low).
In 3 studies,251,253,254 S-100B protein with a threshold ranging
from 0.193 to 2.59mg/L at 24 hours after ROSC predicted poor
neurological outcome from 3 to 6 months with 100% specificity and
sensitivity ranging from 10.1% to 77.6% (certainty of evidence from
moderate to very low). In the same3 studies,251,253,254 S-100Bprotein
with a threshold ranging from 0.159 to 3.67mg/L at 48 hours after
ROSC predicted poor neurological outcome from 3 to 6 months with
100%specificity and sensitivity ranging from5% to 77.6% (certainty of
evidence frommoderate to very low). In the same 3 studies,251,253,254
S-100B protein with a threshold ranging from 0.202 to 1.83mg/L at
72 hours after ROSC predicted poor neurological outcome from 3 to
6 months with 100% specificity and sensitivity ranging from 5% to
61.2% (certainty of evidence from moderate to very low).
Glial Fibrillary Acidic Protein. In 1 study,252 glial fibrillary acidic
protein with a threshold of 0.08mg/L at 48 12hours after ROSC
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predicted poor neurological outcome at 1month with 100% specificity
and 21.3% sensitivity (low-certainty evidence).
Serum Tau Protein. In 1 studywith 667 patients,255 serum tauprotein
with a threshold ranging from 72.7 to 874.5 ng/L at 24 to 72 hours after
ROSC predicted poor neurological outcome at 6 months with 100%
specificity and sensitivity ranging from 4% to 42% (very low-certainty
evidence).
Serum Neurofilament Light Chain. In 1 study,256 serum neurofila-
ment light chain with a threshold ranging from 1539 to 12317 pg/mL at
24 to 72hours after ROSC predicted poor neurological outcome at
6 months with 100% specificity and sensitivity ranging from 53.1% to
65% (moderate certainty of evidence).
In 1 study,257 serum neurofilament light chain with a threshold
ranging from 252 to 405 pg/mL from day 1 to day 7 after ROSC
predicted poor neurological outcome (CPC 4  5) at 6 months with
100% specificity and sensitivity ranging from 55.6% to 94.4% (very
low-certainty evidence).
Treatment Recommendations
We recommend that neuroprognostication always be undertaken by
using a multimodal approach because no single test has sufficient
specificity to eliminate false positives (strong recommendation, very
low-certainty evidence).
We suggest using NSE within 72 hours after ROSC, in
combination with other tests, for predicting neurological outcome
of adults who are comatose after cardiac arrest (weak recommen-
dation, very low-certainty evidence). There is no consensus on a
threshold value.
We suggest against using S-100B protein for predicting neurolog-
ical outcome of adults who are comatose after cardiac arrest (weak
recommendation, low-certainty evidence).
We suggest against using serum levels of glial fibrillary acidic
protein, serum tau protein, or neurofilament light chain for predicting
poor neurological outcome of adults who are comatose after cardiac
arrest (weak recommendation, very low-certainty evidence).
Justification and Evidence-to-Decision Framework Highlights
As was noted in the information addressing this topic in the 2015
CoSTR,1,7 the task force opinion is that amultimodal approach should
be used in all cases with all supplementary tests considered in the
context of prognostication.
The evidence-to-decision tables are included in [1875_TD$DIFF]Supplement
Appendixes A-18, 19, and 20.
Limited evidence suggests that high concentrations ofNSEpredict
poor neurological outcomewith 100%specificity at 24 to 72 hoursafter
cardiac arrest, but there is a wide variability of thresholds for 100%
specificity across studies. Lack of blinding was a limitation in most of
included studies, even if withdrawal of life sustaining therapy based
only on NSE was not documented.
Although the risk of self-fulfilling prophecy for S-100B protein is
lower than that observed in other predictors, the evidence is limited by
the few available studies and the wide variability of thresholds for
100% specificity across studies.
The supporting evidence about the use of neurofilament light
chain, glial fibrillary acidic protein, and serum tau protein for
prognostication after cardiac arrest is limited to very few studies.
Consistent thresholds for 100%specificity need to be identified before
any of these biomarkers can be recommended for prognostication in
the clinical setting. These biomarker tests are not widely available.
The methods used for measuring these biomarkers need to be more
widely available, standardized, and studied.
Knowledge Gaps
 Large cohort studies are desirable to identify consistent NSE and
S-100B thresholds for predicting poor neurological outcome after
cardiac arrest. There is very little evidence concerning the
predictive value of these biomarkers when measured later than
72 hours after ROSC.
 Further studies on glial fibrillary acidic protein, serum tau protein,
and neurofilament light chain are needed to confirm their
predictive value after cardiac arrest, to assess their reproducibility,
and to identify consistent thresholds for 100% specificity.
 The potential impact of TTM on prognostication remains to be
determined.
Imaging for Prognostication (ALS 450, 713, 458: SysRev)
Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults who are comatose after resuscitation from
cardiac arrest in any setting (in-hospital or out-of-hospital) and
regardless of target temperature
 Intervention: Imaging studiesassessedwithin 1weekafter cardiac
arrest
 Comparator: None
 Outcome: Unfavourable neurological outcome defined as CPC
3 to 5 or mRS 4 to 6 at hospital discharge, 1 month, or later
 Study design: Prognostic accuracy studies where the
22 contingency table (ie, the number of true/false negatives
and positives for prediction of poor outcome) was reported, or
where those variables could be calculated from reported data, are
eligible for inclusion. Unpublished studies, reviews, case reports,
case series, studies including fewer than 10 patients, letters,
editorials, conference abstracts, and studies published in abstract
form were excluded.
 Time frame: In 2015,1,7 an ILCOR evidence review identified
4 categories of predictors of neurological outcome after cardiac
arrest, namely clinical examination, biomarkers, electrophysiolo-
gy, and imaging. In the last 4 years, several studies have been
published and new predictors have been identified, therefore the
topic needs an update.
 The most recent search of the previous SysRevs on neuro-
prognostication was launched on May 31, 2013. We searched
studies published from January 1, 2013, to December 31, 2019.
 PROSPERO Registration: CRD42019141169
Consensus on Science
Gray Matter  to  White Matter Ratio.
Gray Matter  to  White Matter Ratio: Average. The prognostic
value of the gray matter  to  white matter ratio (GWR) average was
investigated in 7 observational studies.203,214,258  262 In 4 stud-
ies,214,260,261,263 a GWR average 1.23 or less within 6 hours after
ROSC predicted poor neurological outcome from hospital discharge
to6monthswith100%specificity andsensitivity ranging from13.3% to
83.8% (certainty of evidence from low to very low).
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In 1 study,203 a GWR average 1.13 or less at 124.5 59.9
minutes from ROSC predicted poor neurological outcome at
1 month with 85% specificity and 29.8% sensitivity (very low-
certainty evidence).
In 1 study,259 a GWR average 1.077 or less within 24 hours after
ROSCpredicted poor neurological outcome at hospital dischargewith
100% specificity and 15.6% sensitivity (very low-certainty evidence).
In 1 study,258 a GWR average 1.14 or less within 72 hours after
ROSCpredicted poor neurological outcome at hospital dischargewith
100% specificity and 38.1% sensitivity (very low-certainty evidence).
Gray Matter  to  White Matter Ratio: Basal Ganglia. The
prognostic value of theGWR in the basal ganglia was investigated in 4
observational studies.199,258,261,264 In 1 study,261 GWR-basal ganglia
1.12 or less within 1 hour after ROSC predicted poor neurological
outcome at hospital discharge with 100% specificity and 3.3%
sensitivity (very low-certainty evidence).
In 2 studies,199,264 GWR-basal ganglia 1.21 or less within 24 hours
after ROSC predicted poor neurological outcome at 6 months with
100% specificity and sensitivity ranging from 41.8% to 42.1%
(certainty of evidence from moderate to very low).
In 1 study,258 GWR-basal ganglia 1.12 or lesswithin 72 hours after
ROSCpredicted poor neurological outcome at hospital dischargewith
100% specificity and 28.6% sensitivity (very low-certainty evidence).
Gray Matter  to  White Matter Ratio: Putamen/Corpus Cal-
losum. The prognostic value of the GWR putamen/corpus callosum
was investigated in 3 observational studies.247,260,265
In 2 studies,247,260 theGWRputamen/corpus callosum1.17or less
within 6 hours after ROSC predicted poor neurological outcome from
hospital discharge to 6 months with 100% specificity and sensitivity
ranging from 31.3% to 52.9% (very low-certainty evidence).
In 1 study,265 of 258 patients, the GWR putamen/corpus callosum
0.91 or less within 24 hours after ROSC predicted poor neurological
outcome at 6 months with 100% specificity and 1.7% sensitivity (very
low-certainty evidence).
Gray Matter  to  White Matter Ratio: Simplified (Putamen/
Posterior Limb of Internal Capsule). In 1 observational study, GWR-
simplified258 a ratio 1.1 or less within 72hours after ROSC predicted
poor neurological outcome at hospital dischargewith 100%specificity
and 28.6% sensitivity (very low-certainty evidence).
Gray Matter  to  White Matter Ratio: Caudate Nucleus/Posterior
Limb of Internal Capsule
In 2 observational studies,247,260 a GWR in the caudate nucleus/
posterior limb of the internal capsule 1.15 or less within 6 hours after
ROSC predicted poor neurological outcome from hospital discharge
to6monthswith100%specificity andsensitivity ranging from19.8% to
40.6% (very low-certainty evidence).
Gray Matter  to  White Matter Ratio: Cerebrum. The prognos-
tic value of the GWR in the cerebrum was investigated in 2
observational studies.258,261 In 1 study,261 a GWR in the cerebrum
1.12 or less within 1 hour after ROSC predicted poor neurological
outcome at hospital discharge with 100% specificity and 20%
sensitivity (very low-certainty evidence).
In 1 study,258 a GWR in the cerebrum 1.09 or less within 72 hours
after ROSC predicted poor neurological outcome at hospital
discharge with 100% specificity and 28.6% sensitivity (very low-
certainty evidence).
Gray Matter  to  White Matter Ratio: Thalamus/Corpus Cal-
losum. In 1 observational study,260 aGWR in the cerebrum thalamus/
corpus callosum 1.13 or less at a median time of 90 (IQR, 52  150)
minutes after ROSCpredicted poor neurological outcome at 6months
with 100% specificity and 50% sensitivity (very low-certainty
evidence).
Gray Matter  to  White Matter Ratio: Caudate Nucleus/
Corpus Callosum. In 1 observational study,260 the GWR in the
caudate nucleus/corpus callosum 1.15 or less at median time of 90
(IQR, 52  150) minutes after ROSC predicted poor neurological
outcome at 6monthswith 100%specificity and 46.9% sensitivity (very
low-certainty evidence).
Gray Matter  to  White Matter Ratio in Cardiac Versus
Noncardiac Etiology. One study assessed the predictive value of
GWR specifically in patients with cardiac arrest of cardiac etiology,
and one other focused exclusively on cardiac arrest with noncardiac
etiology.266,267 Both of these studies reported GWRs that had 100%
specificity for poor neurological outcome, and sensitivity was low in all
cases. Results are presented in detail in Tables 3a and 3b.
Diffusion-Weighted MRI. The prognostic value of diffusion-weighted
magnetic resonance imaging (MRI) was investigated in 5 observa-
tional studies.198,214,260,268,269
In 1 study,260 high signal intensity ondiffusion-weightedMRIwithin
6 hours after ROSC predicted poor neurological outcome at 6 months
with 100% specificity and 81.3% sensitivity (very low-certainty
evidence).
In 4 studies,198,214,268,269 positive findings on diffusion-weighted
MRI within 5 days after ROSC predicted poor neurological outcome
from hospital discharge to 6 months with specificity ranging from
55.7% to 100%and sensitivity ranging from26.9% to 92.6% (very low-
certainty evidence).
Apparent Diffusion Coefficient. The prognostic value of apparent
diffusion coefficient (ADC) was investigated in 2 studies.[1880_TD$DIFF]269a
In 1 study,270 a mean ADC 72610   6mm2/s or less at less than
48 hoursafterROSCpredictedpoorneurological outcomeat6months
with 100% specificity and 44% sensitivity (very low-certainty
evidence).
In the same study,270 a mean ADC 627 10   6mm2/s or less at
48 hours to 7 days afterROSCpredicted poor neurological outcomeat
6 months with 100% specificity and 20.8% sensitivity (very low-
certainty evidence).
In the same study,270 an ADC volume proportion (400 10
  6mm2/s) greater than 2.5% at less than 48 hours after ROSC
predicted poor neurological outcome at 6 months with 100%
specificity and 64% sensitivity (very low-certainty evidence).
In the same study,270 an ADC volume proportion (400 10
  6mm2/s) greater than 1.66% at 48 hours to 7 days after ROSC
predicted poor neurological outcome at 6 months with 100%
specificity and 79.2% sensitivity (very low-certainty evidence).
In another study,269a maximum cluster size in different cerebral
regionsonMRI151.7 10   6mm2/s or less at 46 (IQR,37  52) hours
after ROSC predicted poor neurological outcome at 6 months with
100% specificity and sensitivity ranging from 62.5% to 90% (very low-
certainty evidence).
In that same study,269a the lowest mean ADC in different cerebral
regionsonMRI555.7 10   6mm2/s or less at 46 (IQR,37  52) hours
after ROSC predicted poor neurological outcome at 6 months with
100% specificity and sensitivity ranging from 50% to 72.5% (very low-
certainty evidence).
In the same study,269a the lowest minimum ADC in different
cerebral regionsMRI 466.810   6mm2/s or less at 46 (IQR, 37  52)
hours after ROSC predicted poor neurological outcome at 6 months
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with 100% specificity and sensitivity ranging from 42.5% to 82.5%
(very low-certainty evidence).
Treatment Recommendations
We recommend that neuroprognostication always be undertaken by
using a multimodal approach because no single test has sufficient
specificity to eliminate false positives (strong recommendation, very
low-certainty evidence).
We suggest using GWR on brain computed tomography for
predicting neurological outcome of adults who are comatose after
cardiac arrest (weak recommendation, very low-certainty evidence).
However, no GWR threshold for 100% specificity can be
recommended.
We suggest using diffusion-weighted brain MRI for predicting
neurological outcome of adults who are comatose after cardiac arrest
(weak recommendation, very low-certainty evidence).
We suggest using ADC on brain MRI for predicting neurological
outcome of adults who are comatose after cardiac arrest (weak
recommendation, very low-certainty evidence).
Justification and Evidence-to-Decision Framework Highlights
The evidence-to-decision tables are included [1875_TD$DIFF]Supplement Appendix-
es A-21, 22, and 23. As noted in the 2015 CoSTR on this topic,1,7 the
task force consensus is that a multimodal approach should be used in
all cases with all supplementary tests considered in the context of
prognostication.
In patients who are comatose after cardiac arrest, severe brain
edema predicts poor outcome with high specificity. Calculation of
GWRallows a quantitative evaluation of brain edema. However, there
is a wide heterogeneity of measurement techniques (sites and
calculation methods) for GWR. This may partly explain the wide
variability of thresholds for 100% specificity across the identified
studies. The evidence supporting use of the GWR for prognostication
has very low certainty.
Assessing diffusion-weighted imaging has potential for
predicting poor neurological outcome after cardiac arrest. The
definition of a positive diffusion weighted magnetic resonance
image after cardiac arrest was inconsistent or even absent in the
identified studies. The supporting evidence had very low
certainty.
Assessing ADC has a potential for predicting poor neurological
outcome after cardiac arrest with high sensitivity. There is a wide
heterogeneity of measurement techniques (sites and calculation
methods) for ADC across studies. The supporting evidence for ADC
had very low certainty.
Knowledge Gaps
 A consistent GWR threshold for predicting poor neurological
outcome after cardiac arrest should be identified.
 A standardization of the methods for GWR calculation is
warranted.
 The optimal timing for prognostication using brain computed
tomography after cardiac arrest is still unknown. Studies
assessing serial brain computed tomography after cardiac arrest
are desirable.
 The criteria for defining a positive diffusion-weighted MRI after
cardiac arrest need to be standardized.
Table 3a – Sensitivity and Specificity of GWRat 50 (IQR, 26  107)Minutes FromROSC by Brain Location in Patients
With Cardiac Arrest of Cardiac Etiology.
Study, Year GWR Location or Type Sensitivity Specificity Certainty of Evidence
Poor Neurological Outcome at Discharge
Lee, 2015266 1.13 Average 3.5% 100% Very low
1.11 Basal ganglia 3.5% 100% Very low
1.107 Putamen/corpus callosum 5.6% 100% Very low
1.06 Simplified 3.5% 100% Very low
1.094 Caudate nucleus/posterior limb of the internal capsule 3.5% 100% Very low
1.15 Cerebrum 4.2% 100% Very low
GWR indicates gray matter-to-white matter ratio; and IQR, interquartile range.
Table 3b – Sensitivity and Specificity of GWRat 67 (IQR, 29  115)Minutes FromROSC by Brain Location in Patients
With Cardiac Arrest of Noncardiac Etiology.
Study GWR Location or Type Sensitivity Specificity Certainty of Evidence
Poor Neurological Outcome at Discharge
Lee, 2016267 1.22 Average 28.3% 100% Very low
1.17 Basal ganglia 26.2% 100% Very low
1.2 Putamen/corpus callosum 43.4% 100% Very low
1.12 Simplified 9.7% 100% Very low
1.138 Caudate nucleus/posterior limb of the internal capsule 20% 100% Very low
1.2 Cerebrum 11% 100% Very low
GWR indicates gray matter-to-white matter ratio; and IQR, interquartile range.
106 R E S U S C I T A T I O N 1 5 6 ( 2 0 2 0 ) A 8 0   A 1 1 9
 A consistent ADC threshold for predicting poor neurological
outcome after cardiac arrest should be identified.
 Standardization of the methods for ADC calculation is needed.
 The potential impact of TTM on prognostication remains to be
determined.
ALS CoSTR Topics Not Reviewed in 2020
Post-ROSC Percutaneous Coronary Intervention
Updates to 2015 CoSTRs for acute coronary syndromes (ACS) are
now part of ALS postresuscitation care because there is no longer an
ACS Task Force.271,272 The topics of percutaneous coronary
intervention after ROSC in patients with and without ST-segment
elevation (ACS 340, ACS 885) will be addressed in the 2021 CoSTR
after publication of an ongoing SysRev.
Organ Donation After Cardiac Arrest
The 2015 treatment recommendations1,7 have not been updated for
2020. An ILCOR scientific statement on organ donation after OHCA
will provide a narrative summary of the world literature on the
incidence and outcomes of organ donation after OHCA as well as an
estimation of potential donors and published implementation strate-
gies with or without extracorporeal resuscitation. The statement
includes a review of the international ethical issues and provides cost
effectiveness estimates. It will make summary suggestions for
implementation as well as identify key knowledge gaps that need
to be addressed by future research (Tables A1 and A2).
Manual Defibrillation Topics Not Reviewed in 2020
 Algorithm for transition from shockable to nonshockable rhythm
and vice versa (ALS 444)
 Biphasic waveforms (ALS 470)
 Pulsed biphasic waveforms (ALS 470)
 First shock energy (ALS 470)
 Single shocks versus stacked shocks (ALS 470)
 Fixed versus escalating defibrillation energy (ALS 470)
 Cardioversion strategies with implantable cardioverter-defibrilla-
tors or pacemakers (ALS 475)
Circulatory Support Topics Not Reviewed in 2020
 IABP versus manual CPR (ALS 724)
 Open-chest CPR (ALS 574)
 Impedance threshold device (ALS 579)
 Mechanical CPR devices (ALS 782)
Drugs During CPR Topics Not Reviewed in 2020
 IV fluids during cardiac arrest (ALS 578)
 Drugs for atrial fibrillation (ALS 466)
 Drugs for narrow complex tachycardia (ALS 463)
 Drugs for monomorphic wide complex tachycardia (ALS 464)
 Drugs for undifferentiated stable wide complex tachycardia (ALS
583)
 Drugs for bradycardia (ALS 465)
 Atropine for cardiac arrest (ALS 491)
 Calcium for cardiac arrest (ALS 482)
Intra-arrest Monitoring Topics Not Reviewed in 2020
 Point-of-care echocardiography for diagnosis during CPR (ALS
658)
Special Circumstances Topics Not Reviewed in 2020
 Cardiac tamponade (ALS 478)
 Cardiac arrest during coronary catheterization (ALS 479)
 Cardiac arrest in operating room (ALS 812)
 Post-op cardiothoracic surgery cardiac arrest (ALS 572)
 Electrolyte disturbances (ALS 456)
 Digoxin toxicity (ALS 468)
 Tricyclic antidepressant toxicity (ALS 429)
 Cyanide toxicity (ALS 471)
 Cocaine toxicity (ALS 474)
 Carbon monoxide toxicity (ALS 480)
 Calcium channel blocker toxicity (ALS 481)
 Beta blocker toxicity (ALS 485)
 Benzodiazepine toxicity (ALS 486)
 Lipid therapy for cardiac arrest secondary to drug toxicity (ALS
834)
 Avalanche victims (ALS 489)
 Morbid obesity (ALS 452)
 Asthma and cardiac arrest (ALS 492)
 Cardiac arrest caused by anaphylaxis (ALS 494)
Postresuscitation Care Topics Not Reviewed in 2020
 IV fluids after cardiac arrest (ALS 577)
 Mechanical circulatory support postresuscitation (ALS 447)
 Glucose control after resuscitation (ALS 580)
 Haemofiltration postresuscitation (ALS 453)
 Percutaneous coronary intervention after ROSCwith ST-segment
elevation (ACS 340)
 Percutaneous coronary intervention after ROSC without ST-
segment elevation (ACS 885)
 Organ donation (ALS 449)
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